

# BMJ Open

## Cardiovascular Risk Reduction Therapy Effectiveness in South Asian, Chinese, and Other Patients with Diabetes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013808
Article Type:	Research
Date Submitted by the Author:	12-Oct-2016
Complete List of Authors:	Ke, Calvin; Morgan, Steve; University of British Columbia, School of Population and Public Health Smolina, Kate; University of British Columbia, School of Population and Public Health Gasevic, Danijela; University of Edinburgh, Qian, Hong; Center for Health Evaluation and Outcomes Sciences, Medicine Khan, Nadia; University of British Columbia, Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Hypertension < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Cardiovascular Risk Reduction Therapy Effectiveness in South Asian, Chinese, and Other**  
4  
5  
6 **Patients with Diabetes**  
7  
8  
9

10 **Running Title: Cardiovascular Risk Reduction in Diabetes**  
11  
12  
13

14  
15 Authors: Calvin H Ke MD (1), Steve Morgan PhD (2), Kate Smolina PhD (2), Danijela Gasevic  
16  
17 MD, PhD (3), Hong Qian MSc (4), Nadia A Khan MD MSc (1, 4)  
18  
19  
20  
21

22 (1) Department of Medicine, University of British Columbia, Vancouver, British Columbia,  
23 Canada

24 (2) School of Population and Public Health, University of British Columbia, Vancouver,  
25 British Columbia, Canada

26 (3) Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK

27 (4) Center for Health Evaluation and Outcomes Sciences, University of British Columbia,  
28 Vancouver, British Columbia, Canada  
29  
30  
31  
32

33 Corresponding Author:  
34 Nadia Khan MD MSc  
35 620B, 1081 Burrard Street,  
36 Vancouver, BC  
37 P:604 682-2344  
38 F:604 806-8005  
39 nakhanubc@gmail.com  
40  
41  
42

43 Abstract: 246

44 Word Count: 2985

45  
46  
47 Tables & Figures: 4  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** Guidelines recommend angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB) and diuretics in all patients with diabetes mellitus. However, the effectiveness of these agents in South Asian and Chinese populations is unknown. We sought to determine whether ACEi, ARB, CCB, and diuretics are associated with reduced mortality in South Asian, Chinese, and other patients with diabetes.

**Design:** Population-based cohort study using administrative health databases

**Setting:** Province of British Columbia, Canada (2004-2013)

**Participants:** Patients aged  $\geq 35$  years with incident diabetes

**Primary and secondary outcome measures:** Primary outcome was hazard ratio (HR) of mortality on each medication class compared to untreated patients within each ethnicity. Treatment effect was assessed using inverse probability of treatment weighted Cox proportional hazards models. Mortality adjusted for medication adherence was also evaluated.

**Results:** 208,870 patients (13,755 South Asian, 22,871 Chinese, 172,244 other Canadian) were included. ACEi reduced mortality in other patients (HR=0.88, 0.84-0.9) with no significant benefit in Chinese patients. ARB and diuretics reduced mortality in Chinese (ARB HR=0.64, 0.50-0.82; diuretics HR=0.78, 0.62-0.96) and other patients (ARB HR=0.69, 0.64-0.74; diuretics HR=0.66, 0.63-0.69) compared with untreated patients. No mortality benefit was observed among South Asians for any drug class or for CCB among all ethnicities. Higher medication adherence was associated with lower mortality for other patients only (HR=0.80, 0.74-0.85).

**Conclusions:** Effectiveness of cardiovascular risk reduction therapy on mortality varies considerably by ethnicity. Further study is needed to evaluate the lack of mortality benefit of

1  
2  
3 antihypertensive agents in South Asians. Inclusion of these ethnic groups in future clinical trials  
4  
5 is essential to examine for differential responses.  
6  
7  
8  
9

10 Strengths and limitations of this study:

- 11  
12 • This study addresses a substantial gap in the literature regarding long-term effectiveness  
13 of commonly used antihypertensive drug classes among diabetes patients of South Asian  
14 and Chinese descent  
15  
16  
17  
18  
19
- 20 • The analysis is conducted on a large, population-based data set including significant  
21 numbers of people of different ethnicities in Canada, allowing for measurement of real-  
22 world effects on mortality  
23  
24  
25  
26
- 27 • Limitations include possible residual confounding due to unmeasured variables  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Pharmacologic treatment of hypertension in patients with type 2 diabetes mellitus (diabetes) is associated with significantly reduced mortality (1). International guidelines recommend routinely using antihypertensive medications to control blood pressure in all diabetes patients, including those of Asian ethnicity (2–5). However, most trials of cardiovascular risk reduction therapy in patients with diabetes occurred in western populations.

Response to these therapies can be affected by ethnicity. ACE inhibitors (ACEi) were found to be less effective in reducing mortality and cardiovascular events among Black patients with hypertension and diabetes compared with other antihypertensive agents (6,7). Several studies also reported higher risk of ACEi-induced cough in Chinese patients suggesting that there may be some underlying differences in response to these medications (8). Others reported that South Asians may have increased sympathetic activity, possibly causing differing responses to antihypertensive classes (9). An analysis in South Asian and Chinese patients with newly diagnosed diabetes found significant mortality reductions associated with statin use (10). However, similar analyses are currently lacking for antihypertensive agents.

The benefit of ACEi in reducing cardiovascular risk in diabetes was established in multiple large randomized-control trials of western patients, with 24% total mortality reduction seen in the HOPE study (11–13). These benefits were similar to angiotensin receptor blockers (ARB) based on the ONTARGET study subset of diabetes patients (14). However, the PRoFESS trial included 18% of patients of Chinese ethnicity and 8.4% of South Asian ethnicity, found no benefit of telmisartan in reducing major cardiovascular events (15). Additionally, major randomized trials

1  
2  
3 examining thiazide and thiazide-like diuretics ((SHEP (16), ALLHAT (7)), CCB (ALLHAT (7))  
4  
5 and CCB-based combinations (ACCOMPLISH (17)) were conducted in predominantly western  
6  
7  
8 populations.  
9

10  
11  
12 The burden of diabetes in South Asian and Chinese populations is tremendous, with these ethnic  
13  
14 groups representing 62% of all adults with diabetes globally (18). In this context, the paucity of  
15  
16 large studies specifically comparing long-term effectiveness of major antihypertensive drug  
17  
18 classes in these ethnicities is concerning. With the existing, widespread use of these medications,  
19  
20 such studies are unlikely to be conducted in the near future. In an effort to fill the information  
21  
22 gap, we conducted a population-based cohort study to determine whether ACEi, ARB,  
23  
24 dihydropyridine CCB, and diuretics are effective in reducing mortality in a population cohort of  
25  
26 South Asian (originating from Pakistan, India, or Bangladesh), Chinese (originating from China,  
27  
28 Taiwan, or Hong Kong), and other patients with newly diagnosed diabetes.  
29  
30  
31  
32  
33  
34  
35

## 36 **Research Design and Methods**

### 37 *Study Overview*

38  
39  
40  
41 We conducted an analysis using population-based administrative data of adults aged  $\geq 35$  years  
42  
43 living in British Columbia, Canada with newly diagnosed diabetes between April 1, 2004 and  
44  
45  
46  
47  
48  
49  
50  
51 March 31, 2013.  
52  
53  
54

### 55 *Data Sources*

1  
2  
3  
4  
5  
6 We used administrative data from British Columbia, Canada. We obtained de-identified linked  
7  
8 health datasets through Population Data BC with approval of relevant data stewards and the  
9  
10 University of British Columbia's Behavioural Research Ethics Board (19). All inferences,  
11  
12 opinions, and conclusions drawn in this report are those of the authors, and do not reflect the  
13  
14 opinions or policies of Population Data BC.  
15  
16  
17  
18  
19

20 The databases covered all British Columbians except those whose prescription drug coverage fell  
21  
22 under federal jurisdiction (i.e., military, veterans, inmates of federal penitentiaries, and status  
23  
24 Indians living on reserves, approximately 4.0% of the total population). All residents included in  
25  
26 our dataset are covered under British Columbia's universal, public health insurance program for  
27  
28 medical and hospital care; and all are eligible for coverage under British Columbia's universal,  
29  
30 public drug benefit plan, under which deductibles are set in relation to household income.  
31  
32  
33  
34  
35

36 British Columbia has a total population of 4.6 million people, including approximately 210 400  
37  
38 South Asian and 373 800 Chinese people (20, 21). We extracted International Classification of  
39  
40 Diseases (ICD-9 and ICD-10) codes from physician claims including both inpatient and  
41  
42 outpatient encounters. Inpatient data included both primary and secondary discharge diagnosis  
43  
44 codes from hospital discharge abstracts. Data on medication use were extracted from PharmaNet,  
45  
46 a provincial electronic database that contains a record of all dispensed prescriptions from  
47  
48 community pharmacies. The accuracy of this database against prescriptions is estimated to be  
49  
50 greater than 99% (22). Data on time of death were obtained from the vital statistics database and  
51  
52 reporting of all deaths in the province is mandatory.  
53  
54  
55  
56  
57  
58  
59  
60

### *Study Population*

The study population was restricted to people with a new diagnosis of diabetes during the study period. A diagnosis of diabetes was defined as an ICD-9 or ICD-10 code for diabetes for at least one hospital discharge abstract or two physician claims within 2 years (ICD-9-CM: 250.x; ICD-10: E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, and E145). This algorithm was validated against physician diagnosis of diabetes in adults aged  $\geq 35$  years with sensitivity 92% and specificity 97% in identifying diagnoses of diabetes in British Columbia (23–25). A washout period of minimum 3 years was used to identify newly diagnosed diabetes. Index date was defined as the earliest contact with the healthcare system with the diabetes diagnosis. Patients who died within 1 month of medication initiation were excluded from the analysis.

### *Categorizing Ethnic Group*

Because ethnicity is not routinely recorded in Canadian administrative health data, we used an algorithm developed to identify surnames of South Asian and Chinese origin that has been validated for use in administrative data research by Shah et al. (26). Canadian census data show that 93% of South Asians and 90% of Chinese marry people of the same ethnic background, minimizing the chance of misidentification due to mixed marriages (27). We labelled the remaining population as “other.” In the province of British Columbia, the vast majority of this group consists of Caucasian individuals (93%) (28).



### *Sociodemographics and Comorbid Conditions*

We estimated socioeconomic status (SES) using income quintile. We estimated household income based on a combination of household-specific and area-based income data (29). We also included comorbidities from the Charlson comorbid conditions list (30).

### *Cardiovascular Risk Reduction Medications*

Within each ethnicity, we classified study patients as either treated or untreated with each antihypertensive medication class: ARB, ACEi, dihydropyridine CCB, and thiazide or thiazide-type diuretics. We considered patients as treated with a medication if they received at least one prescription within 1 year after index diagnosis, a time period used in other similar studies (10).

### *Outcome Measures*

Patients were followed for up to 4 years for the primary outcome measure, time to death from any cause. Risk was determined for South Asian, Chinese, and other patients treated on each medication as compared to untreated patients within each ethnicity as a baseline.

### *Statistical Analysis*

1  
2  
3 Comparisons of baseline characteristics for each ethnic group were made using the Chi square  
4 test for categorical variables and analysis of variance for continuous variables. We constructed  
5 inverse probability of treatment weighted (IPTW) Cox proportional hazards models for the  
6 treatment effect on mortality to minimize effects of confounding by indication. The weight was  
7 based on a propensity score of having treatment, estimated from a multivariable logistic  
8 regression model with receiving treatment as a binary outcome variable and age, gender, age,  
9 SES, Charlson comorbidities, and baseline use of other medications as independent variables. In  
10 particular, the weight for each subject was computed by taking the inverse probability of  
11 receiving treatment that the subject received and stabilized by multiplying marginal probability  
12 of the actual treatment received (31). Adjusted survival curves were also created for the weighted  
13 sample. Use of other medications (insulin, use of other antihypertensive agents and statins) at  
14 baseline was defined as a prescription recorded within 1 month before or after diagnosis. The  
15 data were censored at the end of the 4-year observation period or at death, whichever came first.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 In a sensitivity analysis to account for effects of differential drug exposure, we evaluated the  
37 association of level of medication adherence with mortality among patients who were treated  
38 with at least one of the four study medication classes. We constructed the weighted Cox  
39 proportional hazards models to compare among the medication adherence levels. In particular,  
40 the adherence of each medication was measured over 1 year since the first prescription using  
41 proportion of days covered (PDC), which has a high predictive validity for hospitalization  
42 episodes (32). The PDC is defined as [(number of days supply of medication in the index  
43 period)/(number of days in the study period)] × 100. The mean PDC across the four classes was  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 calculated and classified into three levels with  $PDC \geq 0.80$  classified as high adherence,  $0.50 \leq$   
4  
5  $PDC < 0.80$  as moderate adherence, and  $PDC < 0.50$  as low adherence.  
6  
7

8  
9  
10 All  $p$  values presented are 2-tailed, and a value of less than 0.05 was considered significant.

11  
12 Analyses were performed with SAS version 9.2 (SAS Institute Inc.).  
13  
14

## 15 16 17 **Results**

### 18 19 20 *Baseline Characteristics and Prescribing*

21  
22  
23  
24  
25  
26  
27 There were 208 870 patients (13 755 South Asian, 22 871 Chinese, 172 244 other) included in  
28  
29 the analysis (Table 1). Most patients were elderly with South Asian patients being younger than  
30  
31 the other groups at time of diagnosis. South Asian and Chinese patients were more likely than  
32  
33 other patients to be in the 2 lowest socioeconomic quintiles. Hypertension was present in almost  
34  
35 half of patients across all ethnicities (42% South Asian, 44% Chinese, 48% other). The  
36  
37 prevalence of comorbid conditions was low in this cohort with South Asian and Chinese patients  
38  
39 having generally a lower prevalence of conditions compared with others, including myocardial  
40  
41 infarction, congestive heart failure, peripheral vascular disease, and cerebrovascular disease.  
42  
43  
44  
45

46  
47  
48 Other patients were the most likely to be prescribed antihypertensive agents at baseline, with the  
49  
50 most frequently prescribed classes being ACEi (23%) and diuretics (18%). South Asians were  
51  
52 also likely to be prescribed with ACEi (16%) and diuretics (11%). Chinese patients had a more  
53  
54 equal distribution among ACEi, ARB, CCB, and diuretic prescriptions (9.1-12%). By the end of  
55  
56  
57  
58  
59  
60

1  
2  
3 one year since initial diabetes diagnosis, almost two-thirds of other patients were prescribed at  
4  
5 least one antihypertensive agent, with a lower proportion in South Asian and Chinese patients.  
6  
7  
8 The most frequently prescribed class of antihypertensive agent by this time was ACEi (26%  
9  
10 South Asians, 18% Chinese, 34% other), followed by diuretics (19% South Asians, 19% Chinese,  
11  
12 27% other).  
13

### 14 15 16 17 *Mortality* 18

19  
20  
21 Overall, 6.5% of patients died during the follow up period (median 3 years; Figure 1). Among  
22  
23 other patients, ACEi (HR=0.88, 0.84-0.91; Table 2), ARB (HR=0.69, 0.64-0.74) and diuretics  
24  
25 (HR=0.66, 0.63-0.69) were associated with substantial reductions in all-cause mortality, with  
26  
27 minimal effect observed with CCB (HR=1.00, 0.94-1.05).  
28  
29

30  
31  
32 Similarly, among Chinese patients, ARB (HR=0.64, 0.50-0.82) and diuretics (HR=0.78, 0.62-  
33  
34 0.96) were associated with significant mortality reduction. There was a non-significant trend  
35  
36 towards benefit with ACEi (HR=0.84, 0.69-1.03), but there was no significant effect observed  
37  
38 with CCB.  
39  
40  
41

42  
43  
44 In South Asian patients, no statistically significant mortality benefits were observed with ACEi  
45  
46 (HR=0.91, 0.71-1.17), ARB (HR=0.88, 0.63-1.25), CCB (HR=1.25, 0.93-1.68), or diuretics  
47  
48 (HR=0.83, 0.61-1.12).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In our sensitivity analysis that included level of drug exposure in all drug classes, a moderate to  
4 high adherence to the 4 antihypertensive classes was associated with lower mortality among  
5 other patients compared to low adherence (Table 3). However, high or moderate adherence was  
6 not associated with reduced mortality compared with low adherence of antihypertensive  
7 medications among Chinese and South Asian patients. There was insufficient power to analyze  
8 the effects of high versus low adherence, or adherence within single medication classes.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **Conclusions**

21  
22  
23  
24 Overall, we observed substantial ethnic differences in effectiveness of cardiovascular risk  
25 reduction therapies on mortality in patients with diabetes. Mortality reduction associated with  
26 treatment with ARB, diuretics and a trend towards mortality benefit with ACEi were observed  
27 Chinese patients. However, no significant associations with mortality and cardiovascular risk  
28 reduction therapy were seen in South Asians for any drug class.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 The findings in the other population in the current analysis are generally consistent with results  
40 from major clinical trials in patients with diabetes (13,14, 33). For ACEi, the benefit we  
41 observed (HR=0.88, 0.84-0.91) is smaller than that reported in the HOPE study (total mortality  
42 relative risk 0.76, 0.63-0.92) that compared ramipril to placebo in patients with diabetes and an  
43 additional cardiovascular risk factor (13). The mortality reduction for ARB (HR=0.69, 0.64-0.74)  
44 is similar to that seen in the LIFE study (relative risk 0.61, 0.45-0.84), comparing losartan to  
45 atenolol (33).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Among Chinese patients, we observed generally similar mortality reductions associated with  
4 ACEi (HR=0.84, 0.69-1.03) and ARB (HR=0.64, 0.50-0.82) use. The magnitude of mortality  
5 reduction is similar to the trials mentioned above, although the benefit of ACEi did not reach  
6 statistical significance. Notably, adherence to ACEi among Chinese patients (52%) compared to  
7 ARB (72%) is reported to be lower than other patients, and this difference may have attenuated  
8 the effect with ACEi (22). Nevertheless, our results provide new evidence on the effectiveness of  
9 these agents in a real world population extending the findings of the ONTARGET (14) study,  
10 that included 14% of patients of Asian ethnicity.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Diuretics were associated with effectiveness in Chinese. The effects observed (Chinese HR=0.77,  
25 0.62-0.96) are largely consistent with those reported in the placebo-controlled SHEP trial (7)  
26 diabetes subgroup (hazard ratio 0.80, 0.68-0.95). The present findings are the first to our  
27 knowledge to evaluate thiazide and thiazide like diuretics to Chinese patients with diabetes.  
28  
29  
30  
31  
32  
33  
34  
35

36 We did not observe substantial benefits of CCB in any ethnic category. This result was  
37 unexpected given the findings of the ALLHAT study, that showed that CCB were equivalent to  
38 ACEi and diuretics as first-line antihypertensive agents in diabetes (7). These findings may  
39 reflect the trend that CCB are decreasingly likely to be used as initial antihypertensive therapy  
40 compared to ACEi and diuretics in Canada (34). This trend is in accordance with guidelines  
41 promoting CCB as an add-on agent given the ACCOMPLISH trial findings (17). Patients in the  
42 CCB group may have had more severe hypertension requiring more than one agent, thereby  
43 causing confounding by indication. Moreover, the comparison group in our study likely included  
44 patients treated with other agents such as ACEi, ARB, and diuretics, leading to an attenuation of  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 observed effect. It is also possible that the real-world effect size varies from that observed in  
4  
5 randomized control trials (RCTs) due to rigid selection criteria and selection bias. Further  
6  
7 research is required to clarify the benefit of CCB, especially in South Asian and Chinese  
8  
9 populations.  
10  
11

12  
13  
14  
15 None of the drug classes were associated with any statistically significant mortality benefits  
16  
17 among South Asians. It is conceivable that the effect may have been attenuated by additional  
18  
19 factors such as cultural dietary practices (e.g. salt intake (35)) and pharmacogenetic influences.  
20  
21 For instance, ACE gene insertion/deletion polymorphisms affect serum levels of ACEi, although  
22  
23 a long-term effect on cardiovascular outcomes has yet to be demonstrated (36). Pharmacogenetic  
24  
25 differences may also lead to heterogeneous responses to antihypertensive agents within the same  
26  
27 class (37). This concerning result may also be due to insufficient power given the relatively low  
28  
29 event rate in this younger incident cohort. With these considerations in mind, further research is  
30  
31 required to confirm the effectiveness and magnitude of mortality benefit of cardiovascular risk  
32  
33 reduction therapy in South Asians.  
34  
35  
36  
37  
38

39  
40  
41 The lack of significant associations among South Asians may also relate to poor medication  
42  
43 adherence and reduced drug exposure. Although we performed a sensitivity analysis using drug  
44  
45 adherence to evaluate whether drug discontinuation, switching between classes, or decreased  
46  
47 adherence may have affected our results, only in other patients was a significant mortality  
48  
49 reduction seen in those with moderate or high adherence. No significant associations were  
50  
51 observed for South Asian and Chinese patients. The lack of adherence effects may be related to  
52  
53 inadequate power to detect smaller treatment related effect size in these groups. South Asian and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Chinese patients may also import antihypertensive medications from out of country, limiting our  
4 ability to detect treatment differences (38). In the context of these limitations, more studies are  
5 required to evaluate the interaction between medication adherence and antihypertensive therapies  
6 in South Asian and Chinese patients.  
7  
8  
9  
10  
11

12  
13  
14  
15 Our large population-based observational study allowed for measurement of real-world effects  
16 on mortality, minimizing outcome misclassification and controlling for confounding using  
17 propensity matching. Observational studies of this nature have been shown to generally correlate  
18 with randomized control trials (39). However, there could have been residual confounding due to  
19 unmeasured variables including blood pressure levels and hemoglobin A1C. Accordingly, further  
20 investigations using different methodologies are required to confirm the present findings.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Given the tremendous and increasing burden of diabetes in South Asian and Chinese patients  
33 globally, there is an alarming paucity of large studies evaluating the effectiveness of routinely  
34 used cardiovascular risk reduction therapies in these groups. ACEi, ARB, and diuretics are likely  
35 effective among Chinese and other patients. More research is required to evaluate the  
36 effectiveness of antihypertensive agents in South Asians, to confirm the benefit of ACEi in  
37 Chinese patients, and to examine CCB effectiveness in all patients. Inclusion of these groups in  
38 future clinical trials is essential to examine for differential response by ethnicity.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Author Contributions

NAK, CK made substantial contributions to conception and design, SM and KS made substantial contributions towards acquisition of data, all authors made substantial contribution to analysis of data, all authors made substantial contribution towards interpretation of data, CK wrote the first draft and all authors participated in revising it critically for important intellectual content; and all authors give final approval of the version submitted.

## Acknowledgements

*Funding and Role of the Sponsor:* This study was funded by the Canadian Institutes of Health Research (CIHR). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NAK is funded by a Michael Smith Foundation for Health Research Career Scientist award.

*Conflict of Interest:* There are no potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present), no relevant financial activities outside the submitted work (over the 3 years prior to submission), and no other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission) for any of the co-authors.

1  
2  
3 Drs. Nadia Khan and Calvin Ke take full responsibility for the work as a whole, including the  
4 study design, access to data, and the decision to submit and publish the manuscript.  
5  
6  
7  
8  
9

10 **Data Sharing Statement:** all datasets are available through Population Data BC, subject to  
11 approval by relevant data stewards at the BC Ministry of Health.  
12  
13  
14  
15  
16  
17  
18  
19

## 20 References

- 21  
22  
23  
24 1. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2  
25 Diabetes Mellitus. *N Engl J Med.* 2010;362(17):1575–85.  
26  
27 2. American Diabetes Association. Standards of Medical Care in Diabetes--2013. *Diabetes*  
28 *Care.* 2012 Dec 20;36(Supplement\_1):S11–66.  
29  
30 3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian  
31 Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management  
32 of Diabetes in Canada. *Can J Diabetes.* 2013 Apr;37(Suppl 1):S1–212.  
33  
34 4. Chatterton H, Younger T, Fischer A, Khunti K. Risk identification and interventions to  
35 prevent type 2 diabetes in adults at high risk: summary of NICE guidance. *BMJ.*  
36 2012;345:e4624.  
37  
38 5. Asian-Pacific Type 2 Diabetes Policy Group. International Diabetes Federation Western  
39 Pacific Region Type 2 Diabetes Practical Targets and Treatment guidelines [Internet].  
40 Melbourne, Australia: International Diabetes Institute; 2005 [cited 2013 Sep 26]. Available  
41 from: <http://www.idf.org/idf-wpr-type-2-diabetes-practical-targets-and-treatments>  
42  
43 6. Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in  
44 hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and  
45 lisinopril. *JAMA.* 2005 Apr 6;293(13):1595–608.  
46  
47 7. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical  
48 outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose  
49 concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to  
50 Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med.* 2005 Jun 27;165(12):1401–9.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
8. Mahmoudpour SH, Leusink M, Putten LVD, Terreehorst I, Asselbergs FW, De Boer A, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. *Pharmacogenomics*. 2013 Feb;14(3):249–60.
9. Gupta AK. Racial Differences in Response to Antihypertensive Therapy: Does One Size Fits All? *Int J Prev Med*. 2010;1(4):217–9.
10. Brunner NW, Ramanathan K, Wang H, Quan H, Khan NA. Effectiveness of Statin Prescribing on Reducing Mortality in South Asian, Chinese, and White Patients With Diabetes. *Can J Cardiol*. 2013 Aug;29(8):920–6.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ*. 1998 Sep 12;317(7160):713–20.
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med*. 1998;338(10):645–52.
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *The Lancet*. 2000 Jan 22;355(9200):253–9.
14. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547–59.
15. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ôunpou S, Lawton WA, et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. *N Engl J Med*. 2008 Sep 18;359(12):1225–37.
16. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. *Am J Cardiol*. 2005 Jan 1;95(1):29–35.
17. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *J Am Coll Cardiol*. 2010 Jun 29;56(1):77–85.
18. International Diabetes Federation. IDF Diabetes Atlas [Internet]. International Diabetes Atlas; 2012 [cited 2013 Jun 19]. Available from: <http://www.idf.org/diabetesatlas/5e/>
19. BC Ministry of Health Data Stewardship Committee, BC Vital Statistics Agency. Consolidation File (MSP Registration & Premium Billing); Discharge Abstracts Database (Hospital Separations) and Medical Services Plan (MSP) Payment Information File; PharmaNet; Vital Statistics Deaths [Internet]. Population Data BC; BC Ministry of Health; 2012–2014. Available from: <http://www.popdata.bc.ca/data>

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Lindsay C. The South Asian Community in Canada [Internet]. Ottawa: Social and Aboriginal Statistics Division, Statistics Canada; 2001 [cited 2013 May 9]. Report No.: 89-621-XIE. Available from: <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2007006-eng.htm#4>
21. Lindsay C. The Chinese Community in Canada [Internet]. Ottawa: Social and Aboriginal Statistics Division, Statistics Canada; 2001 [cited 2013 May 9]. Report No.: 89-621-XIE. Available from: <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2006001-eng.htm>
22. Chong E, Wang H, King-Shier KM, Quan H, Rabi DM, Khan NA. Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with type 2 diabetes mellitus: a population-based cohort study. *Diabet Med J Br Diabet Assoc.* 2014 Dec;31(12):1586–93.
23. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. *The Lancet.* 2007 Mar;369(9563):750–6.
24. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. *Diabetes Res Clin Pract.* 2010 Aug;89(2):189–95.
25. Khan NA, Wang H, Anand S, Jin Y, Campbell NRC, Pilote L, et al. Ethnicity and sex affect diabetes incidence and outcomes. *Diabetes Care.* 2011 Jan;34(1):96–101.
26. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. *BMC Med Res Methodol.* 2010 May 15;10:42.
27. Milan A, Maheux H, Chui T. A portrait of couples in mixed unions. *Can Soc Trends* [Internet]. 2010 Apr 20 [cited 2013 May 9];Summer 2010(89). Available from: <http://www.statcan.gc.ca/pub/11-008-x/2010001/article/11143-eng.htm>
28. Government of Canada SC. Tables by subject: Ethnic diversity and immigration [Internet]. 2013 [cited 2013 Feb 27]. Available from: [http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/ind01/12\\_30000-eng.htm](http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/ind01/12_30000-eng.htm)
29. Hanley GE, Morgan S. On the validity of area-based income measures to proxy household income. *BMC Health Serv Res.* 2008 Apr 10;8:79.
30. Monami M, Lambertucci L, Lamanna C, Lotti E, Marsili A, Masotti G, et al. Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. *Aging Clin Exp Res.* 2007 Dec;19(6):492–6.
31. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med.* 2014 Mar 30;33(7):1242–58.

- 1  
2  
3 32. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for  
4 standardizing adherence measures derived from administrative claims data among diabetic  
5 patients. *Med Care*. 2008;46(11):1125–33.  
6  
7
- 8 33. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al.  
9 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan  
10 Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial  
11 against atenolol. *The Lancet*. 2002 Mar 23;359(9311):1004–10.  
12
- 13 34. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K. Antihypertensive medication  
14 prescribing in 27,822 elderly Canadians with diabetes over the past decade. *Diabetes Care*.  
15 2006;29(4):836–41.  
16
- 17 35. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for  
18 public health. *Int J Epidemiol*. 2009 Jun 1;38(3):791–813.  
19
- 20 36. Yip VLM, Pirmohamed M. Expanding Role of Pharmacogenomics in the Management of  
21 Cardiovascular Disorders. *Am J Cardiovasc Drugs*. 2013 Jun;13(3):151–62.  
22
- 23 37. Tsoi KKF, Wong MCS, Tam WWS, Hirai HW, Lao XQ, Wang HHX, et al. Cardiovascular  
24 mortality in hypertensive patients newly prescribed perindopril vs. lisinopril: A 5-year  
25 cohort study of 15,622 Chinese subjects. *Int J Cardiol*. 2014 Oct 20;176(3):703–9.  
26  
27
- 28 38. Wang L, Kwak M-J. Immigration, barriers to healthcare and transnational ties: A case study  
29 of South Korean immigrants in Toronto, Canada. *Soc Sci Med* 1982. 2015 May;133:340–8.  
30  
31
- 32 39. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, et al. Do  
33 observational studies using propensity score methods agree with randomized trials? A  
34 systematic comparison of studies on acute coronary syndromes. *Eur Heart J*. 2012 Aug  
35 1;33(15):1893–901.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Baseline characteristics among diabetes patients aged 35 years and older\*

Characteristics	South Asian (n=13 755)	Chinese (n=22 871)	Other (n=172 244)
Age, mean age (years) ±SD or %			
All patients	56.4 ±12.6	59.2 ±12.7	61.5 ±12.8
35-49 years	33.2	24.7	18.8
50-64 years	39.8	43.1	42.0
65-79 years	23.2	25.3	29.5
≥80 years	3.87	6.8	9.7
Women (%)	45.0	48.4	45.1
Income Quintile (%)			
1 <sup>st</sup> quintile (low)	25.6	27.4	21.2
2 <sup>nd</sup> quintile	32.2	23.4	20.7
3 <sup>rd</sup> quintile	20.4	20.2	20.0
4 <sup>th</sup> quintile	12.3	14.4	19.3
5th quintile (high)	8.8	13.4	17.5
Unknown	0.7	1.0	1.2
Hypertension	42.0	44.0	47.9
Myocardial infarction	2.2	1.0	2.6
Congestive heart failure	3.0	2.1	5.3
Peripheral vascular disease	0.6	1.3	2.0
Cancer	2.8	3.8	6.3
Cerebrovascular disease	1.8	2.0	3.2
Chronic pulmonary disease	11.2	6.4	11.4
Renal disease	2.2	2.3	3.1
Medications prescribed at baseline n (%)			
ACEi	15.7	11.0	22.8
ARB	7.2	10.0	8.7
CCB	8.1	9.1	8.5
Diuretic	11.3	12.4	18.3
β-blocker	9.5	8.4	13.3
Metformin	21.3	15.4	23.8
Sulfonylurea	3.8	2.6	3.5
Insulin	0.6	0.7	1.7
Statin	24.2	20.8	26.9
Medications prescribed after 1 year of diabetes diagnosis n (%)			
ACEi	26.1	17.8	33.5
ARB	12.6	16.3	13.7
CCB	12.6	13.9	12.8
Diuretic	18.7	18.6	27.0
Any ACEi, ARB, CCB, diuretic**	55.2	47.7	64.9

\*All p-values comparing the 3 ethnic groups were less than 0.001

\*\*Abbreviations: SD = standard deviation, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 2** Association between antihypertensive medications and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian (n=13 755)	p-value	Chinese (n=22 871)	p-value	Other (n=172 244)	p-value
ACEi	0.91 (0.71-1.17)	0.47	0.84 (0.69-1.03)	0.09	0.88 (0.84-0.91)	<0.0001
ARB	0.88 (0.63-1.25)	0.48	0.64 (0.50-0.82)	0.0004	0.69 (0.64-0.74)	<0.0001
CCB	1.25 (0.93-1.68)	0.14	0.94 (0.77-1.15)	0.56	1.00 (0.94-1.05)	0.89
Diuretic	0.83 (0.61-1.12)	0.22	0.77 (0.62-0.96)	0.02	0.66 (0.63-0.69)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 3** Association between medication adherence and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian (n=13 755)	p-value	Chinese (n=22 871)	p-value	Other (n=172 244)	p-value
Any ACEi, ARB, CCB, diuretic <sup>†</sup>	0.94 (0.68-1.31)	0.73	1.12 (0.82-1.54)	0.46	0.80 (0.74-0.85)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

<sup>†</sup> Hazard ratios for patients prescribed any antihypertensive (ACEi, ARB, CCB, diuretic) with moderate or high adherence compared to low adherence

Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker




1  
2  
3 **Figure 1** Adjusted\* Kaplan-Meier survival curves for patients treated with ACEi, ARB, CCB,  
4 and diuretics (“DIU”) according to ethnicity: (A) South Asian; (B) Chinese; (C) Other  
5  
6


7 *(see Figure 1A, 1B, 1C files attached separately)*  
8

9 \* Cox proportional hazards models were weighted using a propensity score model by the IPTW  
10 method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin,  
11 ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription  
12 within 1 month before or after diagnosis.  
13


14 Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor  
15 blocker, CCB = dihydropyridine calcium channel blocker  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60







1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40



## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract <b>[title page 1 and abstract page 2]</b> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>[abstract page 2]</b>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>[introduction page 4]</b>
Objectives	3	State specific objectives, including any prespecified hypotheses <b>[introduction page 5]</b>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper <b>[methods page 5]</b>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>[methods pages 5-7]</b>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>[methods pages 5-8]</b> <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <b>[methods page 9]</b> <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>[methods pages 7-9]</b>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>[methods pages 8-9]</b>
Bias	9	Describe any efforts to address potential sources of bias <b>[methods page 9]</b>
Study size	10	Explain how the study size was arrived at <b>[methods page 6]</b>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>[methods page 9]</b>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>[methods pages 9-10]</b> (b) Describe any methods used to examine subgroups and interactions N/A (c) Explain how missing data were addressed N/A (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed N/A <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses <b>[methods page 9]</b>

Continued on next page

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <b>[results page 10]</b> (b) Give reasons for non-participation at each stage <b>N/A</b> (c) Consider use of a flow diagram <b>N/A</b>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <b>[page 21 Table 1]</b> (b) Indicate number of participants with missing data for each variable of interest <b>[page 21 Table 1]</b> (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) <b>[results page 11]</b>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <b>[results page 11]</b> <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <b>[page 22 Table 2]</b> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <b>[page 22 Table 3]</b>

**Discussion**

Key results	18	Summarise key results with reference to study objectives <b>[Discussion page 12]</b>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <b>[Discussion page 15]</b>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <b>[Discussion pages 12-15]</b>
Generalisability	21	Discuss the generalisability (external validity) of the study results <b>[Discussion page 15]</b>

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <b>[page 16]</b>
---------	----	--

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Is Cardiovascular Risk Reduction Therapy Effective in South Asian, Chinese, and Other Patients with Diabetes? A Population-Based Cohort Study from Canada

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013808.R1
Article Type:	Research
Date Submitted by the Author:	06-Apr-2017
Complete List of Authors:	Ke, Calvin; University of Toronto Morgan, Steve; University of British Columbia, School of Population and Public Health Smolina, Kate; University of British Columbia, School of Population and Public Health Gasevic, Danijela; University of Edinburgh, Qian, Hong; Center for Health Evaluation and Outcomes Sciences, Medicine Khan, Nadia; University of British Columbia, Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Hypertension < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Only

1  
2  
3 **Is Cardiovascular Risk Reduction Therapy Effective in South Asian, Chinese, and Other**  
4  
5 **Patients with Diabetes? A Population-Based Cohort Study from Canada**  
6  
7  
8  
9

10 **Running Title: Cardiovascular Risk Reduction in Diabetes**  
11  
12  
13

14  
15 Authors: Calvin H Ke MD (1), Steve Morgan PhD (2), Kate Smolina PhD (2), Danijela Gasevic  
16  
17 MD, PhD (3), Hong Qian MSc (4), Nadia A Khan MD MSc (1, 4)  
18  
19  
20  
21

22 (1) Department of Medicine, University of British Columbia, Vancouver, British Columbia,  
23 Canada

24 (2) School of Population and Public Health, University of British Columbia, Vancouver,  
25 British Columbia, Canada

26 (3) Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK

27 (4) Center for Health Evaluation and Outcomes Sciences, University of British Columbia,  
28 Vancouver, British Columbia, Canada  
29  
30  
31  
32

33 Corresponding Author:  
34 Nadia Khan MD MSc  
35 620B, 1081 Burrard Street,  
36 Vancouver, BC  
37 P:604 682-2344  
38 F:604 806-8005  
39 nakhanubc@gmail.com  
40  
41  
42

43 Abstract: 265 words

44 Manuscript: 3511 words

45  
46  
47  
48 Tables & Figures: 4  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Abstract

**Objectives:** Guidelines recommend angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB) and diuretics in all patients with diabetes mellitus. However, the effectiveness of these agents in South Asian and Chinese populations is unknown. We sought to determine whether ACEi, ARB, CCB, and diuretics are associated with reduced mortality in South Asian, Chinese, and other patients with diabetes.

**Design:** Population-based cohort study using administrative health databases

**Setting:** Province of British Columbia, Canada (2006-2013)

**Participants:** Patients aged  $\geq 35$  years with incident diabetes

**Primary and secondary outcome measures:** Primary outcome was all-cause mortality for each medication class compared to untreated patients within each ethnicity. Treatment effect was assessed using inverse probability of treatment weighted Cox proportional hazards models. Medication adherence effect on mortality was also evaluated.

**Results:** 208,870 patients (13,755 South Asian, 22,871 Chinese, 172,244 other Canadian) were included. ACEi reduced mortality in other patients (HR=0.88, 0.84-0.91) with no significant benefit in Chinese and South Asian patients. ARB and diuretics reduced mortality in Chinese (ARB HR=0.64, 0.50-0.82; diuretics HR=0.77, 0.62-0.96) and other patients (ARB HR=0.69, 0.64-0.74; diuretics HR=0.66, 0.63-0.69) compared with untreated patients. No mortality benefit was observed among South Asians for any drug class or for CCB among all ethnicities. Higher medication adherence was associated with lower mortality for other patients only (HR=0.79, 0.72-0.86).

1  
2  
3 **Conclusions:** Effectiveness of cardiovascular risk reduction therapy on mortality varies  
4  
5 considerably by ethnicity. Further study is needed to evaluate the lack of mortality benefit of  
6  
7 antihypertensive agents in South Asians. Inclusion of these ethnic groups in future clinical trials  
8  
9 is essential to examine for differential responses.  
10  
11  
12  
13

14  
15 Strengths and limitations of this study:  
16

- 17 • This study addresses a substantial gap in the literature regarding long-term effectiveness  
18 of commonly used antihypertensive drug classes among diabetes patients of South Asian  
19 and Chinese descent  
20  
21
  - 22 • The analysis is conducted on a large, population-based data set including significant  
23 numbers of people of different ethnicities in Canada, allowing for measurement of real-  
24 world effects on mortality  
25  
26
  - 27 • Limitations include possible residual confounding due to unmeasured variables  
28  
29  
30  
31  
32
- 33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Pharmacologic treatment of hypertension in patients with type 2 diabetes mellitus (diabetes) is associated with significantly reduced mortality (1). International guidelines recommend routinely using antihypertensive medications to control blood pressure in all diabetes patients, including those of Asian ethnicity (2–5). However, most trials of cardiovascular risk reduction therapy in patients with diabetes occurred in western populations.

Response to these therapies can be affected by ethnicity. ACE inhibitors (ACEi) were found to be less effective in reducing mortality and cardiovascular events among Black patients with hypertension and diabetes compared with other antihypertensive agents (6–8). Several studies also reported higher risk of ACEi-induced cough in Chinese patients suggesting that there may be some underlying differences in response to these medications (9). Others reported that South Asians may have increased sympathetic activity, possibly causing differing responses to antihypertensive classes (10). An analysis in South Asian and Chinese patients with newly diagnosed diabetes found significant mortality reductions associated with statin use (10). However, similar analyses are currently lacking for antihypertensive agents.

The benefit of ACEi in reducing cardiovascular risk in diabetes was established in multiple large randomized-control trials of western patients, with 24% reduction in the secondary outcome of total mortality seen in the HOPE study (11–13). These benefits were similar to angiotensin receptor blockers (ARB) based on the ONTARGET study subset of diabetes patients (14). However, the PROfESS trial included 18% of patients of Chinese ethnicity and 8.4% of South Asian ethnicity, found no benefit of telmisartan in reducing major cardiovascular events (15).

1  
2  
3 Additionally, major randomized trials examining thiazide and thiazide-like diuretics ((SHEP (16),  
4 ALLHAT (7)), CCB (ALLHAT (7)) and CCB-based combinations (ACCOMPLISH (17)) were  
5  
6 conducted in predominantly western populations.  
7  
8  
9

10  
11  
12 The burden of diabetes in South Asian and Chinese populations is tremendous, with these ethnic  
13 groups representing 62% of all adults with diabetes globally (18). In this context, the paucity of  
14 large studies specifically comparing long-term effectiveness of major antihypertensive drug  
15 classes in these ethnicities is concerning (19). With the existing, widespread use of these  
16 medications, such studies are unlikely to be conducted in the near future. In an effort to fill the  
17 information gap, we conducted a population-based cohort study to determine whether ACEi,  
18 ARB, dihydropyridine CCB, and diuretics are effective in reducing all-cause mortality in a  
19 population cohort of South Asian (originating from Pakistan, India, or Bangladesh), Chinese  
20 (originating from China, Taiwan, or Hong Kong), and other patients with newly diagnosed  
21 diabetes.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Research Design and Methods**

### 40 41 42 43 *Study Overview*

44  
45  
46  
47  
48 We conducted an analysis using population-based administrative data of adults aged  $\geq 35$  years  
49 living in British Columbia, Canada with newly diagnosed diabetes between April 1, 2006 and  
50  
51 March 31, 2013.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Data Sources*

We used administrative data from British Columbia, Canada. We obtained de-identified linked health datasets through Population Data BC with approval of relevant data stewards and the University of British Columbia's Behavioural Research Ethics Board (20). All inferences, opinions, and conclusions drawn in this report are those of the authors, and do not reflect the opinions or policies of Population Data BC.

The databases covered all British Columbians except those whose prescription drug coverage fell under federal jurisdiction (i.e., military, veterans, inmates of federal penitentiaries, and status Indians living on reserves, approximately 4.0% of the total population). All residents included in our dataset are covered under British Columbia's universal, public health insurance program for medical and hospital care; and all are eligible for coverage under British Columbia's universal, public drug benefit plan, under which deductibles are set in relation to household income.

British Columbia has a total population of 4.6 million people, including approximately 210 400 South Asian and 373 800 Chinese people (21,22). Because the public health insurance program covers virtually all health encounters, data from physician billing claims can be used to identify diagnoses. We extracted International Classification of Diseases (ICD-9 and ICD-10) codes from physician claims including both inpatient and outpatient encounters. Outpatient billing data include a single diagnosis for each encounter. Inpatient data include both primary (most responsible diagnosis) and secondary (comorbid conditions) diagnosis codes from hospital discharge abstracts (up to 25 codes for each encounter). Data on medication use were extracted

1  
2  
3 from PharmaNet, a provincial electronic database that contains a record of all dispensed  
4  
5 prescriptions from community pharmacies. The accuracy of this database against prescriptions is  
6  
7 estimated to be greater than 99% (23). Data on time of death were obtained from the vital  
8  
9 statistics database and reporting of all deaths in the province is mandatory.  
10  
11

### 12 13 14 15 *Study Population*

16  
17  
18  
19  
20 The study population was restricted to people with a new diagnosis of diabetes during the study  
21  
22 period. A new diagnosis of diabetes was defined as an ICD-9 or ICD-10 code for diabetes for at  
23  
24 least one hospital discharge abstract or two physician claims within 2 years (ICD-9-CM: 250.x;  
25  
26 ICD-10: E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, and E145). To  
27  
28 ensure that these cases were truly new diagnoses, we set a washout period of 3 years (i.e., no  
29  
30 physician claims for diabetes in the preceding 3 years). This algorithm is entirely based on  
31  
32 administrative billing data, and was previously validated against physician diagnosis of diabetes  
33  
34 in adults aged  $\geq 35$  years with sensitivity 92% and specificity 97% in identifying diagnoses of  
35  
36 diabetes in British Columbia (24–26). Index date was defined as the earliest contact with the  
37  
38 healthcare system with the diabetes diagnosis. Patients who died within 1 month of diabetes  
39  
40 diagnosis were excluded from the analysis.  
41  
42  
43  
44  
45  
46  
47

### 48 49 *Categorizing Ethnic Group*

50  
51  
52  
53 Because ethnicity is not routinely recorded in Canadian administrative health data, we used an  
54  
55 algorithm developed to identify surnames of South Asian and Chinese origin that has been  
56  
57  
58  
59  
60

1  
2  
3 validated for use in administrative data research by Shah et al. (27). Canadian census data show  
4  
5 that 93% of South Asians and 90% of Chinese marry people of the same ethnic background,  
6  
7 minimizing the chance of misidentification due to mixed marriages (28). We labelled the  
8  
9 remaining population as “other.” In the province of British Columbia, the vast majority of this  
10  
11 group consists of Caucasian individuals (93%) (29).  
12  
13

### 14 15 16 17 18 *Sociodemographics and Comorbid Conditions*

19  
20  
21 We estimated socioeconomic status (SES) using income quintile. We estimated household  
22  
23 income based on a combination of household-specific and area-based income data (30). We also  
24  
25 included comorbidities from the Charlson comorbid conditions list (31). These conditions were  
26  
27 extracted from all inpatient and outpatient claims dating from up to 1 year prior to the index date.  
28  
29  
30  
31  
32

### 33 34 *Cardiovascular Risk Reduction Medications*

35  
36  
37  
38 Within each ethnicity, we classified study patients as either treated or untreated with each  
39  
40 antihypertensive medication class: ARB, ACEi, dihydropyridine CCB, and thiazide or thiazide-  
41  
42 type diuretics. We considered patients as treated with a medication if they received at least one  
43  
44 prescription within 1 year after index diagnosis, a time period used in other similar studies (32).  
45  
46  
47  
48  
49

### 50 51 *Outcome Measures*

1  
2  
3 Patients were followed for up to 4 years for the primary outcome measure, time to death from  
4 any cause. Risk was determined for South Asian, Chinese, and other patients treated on each  
5 medication as compared to untreated patients (regardless of other antihypertensive use) within  
6 each ethnicity as a baseline.  
7  
8  
9  
10  
11

### 12 13 14 15 *Statistical Analysis* 16

17  
18  
19  
20 Baseline characteristics for each ethnic group were summarized and compared among the groups  
21 using the Chi square test for categorical variables and analysis of variance for continuous  
22 variables. We constructed inverse probability of treatment weighted (IPTW) Cox proportional  
23 hazards models for the treatment effect on mortality (33,34). This method is aimed at minimizing  
24 effects of confounding by indication (35). The weight was based on a propensity score of having  
25 treatment, estimated from a multivariable logistic regression model with receiving treatment as a  
26 binary outcome variable and age, gender, SES, Charlson comorbidities, and baseline use of other  
27 medications as independent variables. In particular, the weight for each subject was computed by  
28 taking the inverse probability of receiving treatment that the subject received and stabilized by  
29 multiplying marginal probability of the actual treatment received (36). Means and standard  
30 deviations of the weights were assessed to verify the positivity assumption. The proportional  
31 hazards assumption was verified using Schoenfeld residuals. Cumulative incidence of death was  
32 also visualized for the weighted sample. Use of other medications (insulin, use of other  
33 antihypertensive agents and statins) at baseline was defined as a prescription recorded within 1  
34 month before or after diagnosis. The data were censored at the end of the 4-year observation  
35 period or at death, whichever came first.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 In a sensitivity analysis to account for effects of differential drug exposure, we evaluated the  
7  
8 association of level of medication adherence with mortality among patients who were treated  
9  
10 with at least one of the four study medication classes. We constructed the IPTW Cox  
11  
12 proportional hazards models to compare among the medication adherence levels. In particular,  
13  
14 the adherence of each medication was measured over 1 year since the first prescription using  
15  
16 proportion of days covered (PDC), which has a high predictive validity for hospitalization  
17  
18 episodes (37). The PDC is defined as [(number of days supply of medication in the index  
19  
20 period)/(number of days in the study period)]  $\times$  100. The mean PDC across the four classes was  
21  
22 calculated and classified into three levels with  $PDC \geq 0.80$  classified as high adherence,  $0.50 \leq$   
23  
24  $PDC < 0.80$  as moderate adherence, and  $PDC < 0.50$  as low adherence.  
25  
26  
27  
28  
29  
30  
31

32 All  $p$  values presented are 2-tailed, and a value of less than 0.05 was considered significant.

33  
34 Analyses were performed with SAS version 9.4 (SAS Institute Inc.).  
35  
36  
37  
38

## 39 **Results**

### 40 41 42 43 *Baseline Characteristics and Prescribing* 44 45 46 47

48 There were 208 870 patients (13 755 South Asian, 22 871 Chinese, 172 244 other) included in  
49  
50 the analysis (Table 1). Most patients were elderly with South Asian patients being younger than  
51  
52 the other groups at time of diagnosis. South Asian and Chinese patients were more likely than  
53  
54 other patients to be in the 2 lowest socioeconomic quintiles. Hypertension was present in almost  
55  
56  
57  
58  
59  
60

1  
2  
3 half of patients across all ethnicities (42% South Asian, 44% Chinese, 48% other). The  
4  
5 prevalence of comorbid conditions was low in this cohort with South Asian and Chinese patients  
6  
7 having generally a lower prevalence of conditions compared with others, including myocardial  
8  
9 infarction, congestive heart failure, peripheral vascular disease, and cerebrovascular disease.  
10  
11

12  
13  
14  
15 Other patients were the most likely to be prescribed antihypertensive agents at baseline, with the  
16  
17 most frequently prescribed classes being ACEi (23%) and diuretics (18%). South Asians were  
18  
19 also likely to be prescribed with ACEi (16%) and diuretics (11%). Chinese patients had a more  
20  
21 equal distribution among ACEi, ARB, CCB, and diuretic prescriptions (9.1-12%). By the end of  
22  
23 one year since initial diabetes diagnosis, almost two-thirds of other patients were prescribed at  
24  
25 least one antihypertensive agent, with a lower proportion in South Asian and Chinese patients.  
26  
27 The most frequently prescribed class of antihypertensive agent by this time was ACEi (26%  
28  
29 South Asians, 18% Chinese, 34% other), followed by diuretics (19% South Asians, 19% Chinese,  
30  
31 27% other).  
32  
33  
34  
35  
36  
37  
38

### 39 *Mortality*

40  
41  
42  
43 Overall, 6.5% of patients died during the follow up period (median 3 years; Figure 1). Among  
44  
45 other patients, ACEi (HR=0.88, 0.84-0.91; Table 2), ARB (HR=0.69, 0.64-0.74) and diuretics  
46  
47 (HR=0.66, 0.63-0.69) were associated with substantial reductions in all-cause mortality, with  
48  
49 minimal effect observed with CCB (HR=1.00, 0.94-1.05). Consistent with the positivity  
50  
51 assumption, the means of the stabilized weights were close to one with low standard deviations  
52  
53  
54  
55 (Supplemental Table S1).  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Similarly, among Chinese patients, ARB (HR=0.64, 0.50-0.82) and diuretics (HR=0.77, 0.62-  
6 0.96) were associated with significant mortality reduction. There was a non-significant trend  
7  
8 towards benefit with ACEi (HR=0.84, 0.69-1.03), but there was no significant effect observed  
9  
10 with CCB.  
11  
12

13  
14  
15  
16  
17 In South Asian patients, no statistically significant mortality benefits were observed with ACEi  
18 (HR=0.91, 0.71-1.17), ARB (HR=0.88, 0.63-1.25), CCB (HR=1.25, 0.93-1.68), or diuretics  
19 (HR=0.83, 0.61-1.12).  
20  
21  
22  
23

24  
25  
26  
27 In our sensitivity analysis that included level of drug exposure in all drug classes, a moderate to  
28 high adherence to the 4 antihypertensive classes was associated with lower mortality among  
29 other patients compared to low adherence (Table 3). However, high or moderate adherence was  
30 not associated with reduced mortality compared with low adherence of antihypertensive  
31 medications among Chinese and South Asian patients. There was insufficient power to analyze  
32 the effects of high versus low adherence, or adherence within single medication classes.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 Discussion

44  
45  
46  
47

48 Overall, we observed substantial ethnic differences in effectiveness of cardiovascular risk  
49 reduction therapies on mortality in patients with diabetes. Mortality reduction associated with  
50 treatment with ARB, diuretics and a trend towards mortality benefit with ACEi were observed  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Chinese patients. However, no significant associations with mortality and cardiovascular risk  
4  
5 reduction therapy were seen in South Asians for any drug class.  
6  
7  
8  
9

10 It is difficult to directly compare our findings with those of previous major clinical trials due to  
11  
12 differences in study methodology, inability to directly compare the magnitude of hazards ratios  
13  
14 and relative risks, and due to the specification of all-cause mortality as a non-primary outcome in  
15  
16 most of these trials. Nevertheless, the effects we observed in the other population are generally  
17  
18 consistent in direction with results from major clinical trials in patients with diabetes (13,14, 33).  
19  
20 For ACEi, the benefit we observed (HR=0.88, 0.84-0.91) is consistent with findings reported in  
21  
22 the HOPE study (total mortality relative risk 0.76, 0.63-0.92) that compared ramipril to placebo  
23  
24 in patients with diabetes and an additional cardiovascular risk factor (13). The mortality  
25  
26 reduction for ARB (HR=0.69, 0.64-0.74) is similar to that seen in the LIFE study (relative risk  
27  
28 0.61, 0.45-0.84), comparing losartan to atenolol (38).  
29  
30  
31  
32  
33  
34  
35

36 Among Chinese patients, we observed generally similar mortality reductions associated with  
37  
38 ACEi (HR=0.84, 0.69-1.03) and ARB (HR=0.64, 0.50-0.82) use, although the benefit of ACEi  
39  
40 did not reach statistical significance. Notably, adherence to ACEi among Chinese patients (52%)  
41  
42 compared to ARB (72%) is reported to be lower than other patients, and this difference may have  
43  
44 attenuated the effect with ACEi (23). Nevertheless, our results provide new evidence on the  
45  
46 effectiveness of these agents in a real world population extending the findings of the  
47  
48 ONTARGET (14) study, that included 14% of patients of Asian ethnicity. Given these findings,  
49  
50 it is particularly important to emphasize the increased use of these medications, particularly  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 given the gaps in prescription filling observed among Chinese and South Asian patients, who had  
4  
5 lower than expected rates of renin-angiotensin system antagonist prescription.  
6  
7  
8  
9

10 Diuretics were associated with effectiveness in Chinese. The effects observed (Chinese HR=0.77,  
11  
12 0.62-0.96) are largely consistent with those reported in the placebo-controlled SHEP trial (16)  
13  
14 diabetes subgroup (HR 0.80, 0.68-0.95). The present findings are the first to our knowledge to  
15  
16 evaluate thiazide and thiazide like diuretics to Chinese patients with diabetes.  
17  
18  
19

20  
21  
22 We did not observe substantial benefits of CCB in any ethnic category. This result was  
23  
24 unexpected given the findings of the ALLHAT study, that showed that CCB were equivalent to  
25  
26 ACEi and diuretics as first-line antihypertensive agents in diabetes (7). These findings may  
27  
28 reflect the trend that CCB are decreasingly likely to be used as initial antihypertensive therapy  
29  
30 compared to ACEi and diuretics in Canada (39). This trend is in accordance with guidelines  
31  
32 promoting CCB as an add-on agent given the ACCOMPLISH trial findings (17). Patients in the  
33  
34 CCB group may have had more severe hypertension requiring more than one agent, thereby  
35  
36 causing confounding by indication. Moreover, the comparison group in our study likely included  
37  
38 patients treated with other agents such as ACEi, ARB, and diuretics, leading to an attenuation of  
39  
40 observed effect. It is also possible that the real-world effect size varies from that observed in  
41  
42 randomized control trials (RCTs) due to rigid selection criteria and selection bias. Further  
43  
44 research is required to clarify the benefit of CCB, especially in South Asian and Chinese  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
populations.

1  
2  
3 None of the drug classes were associated with any statistically significant mortality benefits  
4 among South Asians. A major reason for the lack of findings could have been a lack of power  
5 (Supplemental Table S2) given low event rates (355 events, 2.6% event rate in South Asians;  
6 679 events, 3.0% in Chinese) and low prescription filling rates in this cohort. The lower rate of  
7 mortality events is consistent with evidence in our population demonstrating a lower rate of  
8 mortality following myocardial infarction, uniquely among South Asians (40). It is conceivable  
9 that the effect may also have been attenuated by additional factors such as cultural dietary  
10 practices (e.g. salt intake (41)) and pharmacogenetic influences. For instance, ACE gene  
11 insertion/deletion polymorphisms affect serum levels of ACEi, although a long-term effect on  
12 cardiovascular outcomes has yet to be demonstrated (42). Pharmacogenetic differences may also  
13 lead to heterogeneous responses to antihypertensive agents within the same class (43). With  
14 these considerations in mind, further research is required to confirm the effectiveness and  
15 magnitude of mortality benefit of cardiovascular risk reduction therapy in South Asians.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The lack of significant associations among South Asians may also relate to poor medication  
37 adherence and reduced drug exposure. Although we performed a sensitivity analysis using drug  
38 adherence to evaluate whether drug discontinuation, switching between classes, or decreased  
39 adherence may have affected our results, only in other patients was a significant mortality  
40 reduction seen in those with moderate or high adherence. No significant associations were  
41 observed for South Asian and Chinese patients. The lack of adherence effects may be related to  
42 inadequate power to detect smaller treatment related effect size in these groups. South Asian and  
43 Chinese patients may also import antihypertensive medications from out of country, limiting our  
44 ability to detect treatment differences (44). In the context of these limitations, more studies are  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 required to evaluate the interaction between medication adherence and antihypertensive therapies  
4  
5 in South Asian and Chinese patients.  
6  
7  
8  
9

10 Our large population-based observational study allowed for measurement of real-world effects  
11 on mortality, minimizing outcome misclassification and with virtually no loss to follow-up in the  
12 context of Canada's universal healthcare system. Although observational studies of this nature  
13 have been shown to generally correlate with randomized control trials (45), we recognize that  
14 our cohort had lower prevalence of comorbid conditions compared to the more high-risk  
15 populations included in clinical trials. Thus, it is possible that a mortality benefit for ACEi and  
16 other cardiovascular risk reduction therapies may indeed exist among the subset of high-risk  
17 South Asian (and Chinese) patients that was not captured in this study. Additional studies with a  
18 larger sample size (given the relative lack of power in the South Asian cohort) or with a higher-  
19 risk cohort would be required to evaluate this possibility. Moreover, the IPTW can be used to  
20 estimate exposure effects adjusted for measured confounders only. However, there could have  
21 been residual confounding due to unmeasured variables including hypertension severity and  
22 duration, age of hypertension onset, treatment indication, treatment of previous cardiovascular  
23 comorbidities, blood pressure levels, and hemoglobin A1C. Finally, there is a built-in selection  
24 bias that has been described with use of hazard ratios (46). Given the limitations we have  
25 described, further investigations using different methodologies are required to confirm the  
26 present findings.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51  
52 Given the tremendous and increasing burden of diabetes in South Asian and Chinese patients  
53 globally, there is an alarming paucity of large studies evaluating the effectiveness of routinely  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 used cardiovascular risk reduction therapies in these groups. ACEi, ARB, and diuretics are likely  
4  
5 effective among Chinese and other patients. Although it is likely that these drugs are effective in  
6  
7 high-risk diabetes patients across all ethnicities including South Asians, we were unable to  
8  
9 demonstrate this with our usual-risk population. Given that this study was not a randomized  
10  
11 controlled trial examining antihypertensive efficacy in these populations, these findings should  
12  
13 be interpreted with caution. More research is required to evaluate the effectiveness of  
14  
15 antihypertensive agents in South Asians, and to confirm the benefit of ACEi in Chinese patients.  
16  
17 Inclusion of these groups in future clinical trials is essential to examine for differential response  
18  
19 by ethnicity.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Author Contributions**

35  
36  
37 NAK, CK made substantial contributions to conception and design, SM and KS made substantial  
38  
39 contributions towards acquisition of data, all authors made substantial contribution to analysis of  
40  
41 data, all authors made substantial contribution towards interpretation of data, CK wrote the first  
42  
43 draft and all authors participated in revising it critically for important intellectual content; and all  
44  
45 authors give final approval of the version submitted.  
46  
47  
48  
49  
50

### 51 **Acknowledgements**



1  
2  
3 *Funding and Role of the Sponsor:* This study was funded by the Canadian Institutes of Health  
4 Research (CIHR). The study sponsors had no role in the design and conduct of the study;  
5  
6 collection, management, analysis, and interpretation of the data; and preparation, review, or  
7  
8 approval of the manuscript. NAK is funded by a Michael Smith Foundation for Health Research  
9  
10  
11  
12  
13 Career Scientist award.

14  
15  
16  
17 *Conflict of Interest:* There are no potential conflicts of interest involving the work under  
18  
19 consideration for publication (during the time involving the work, from initial conception and  
20  
21 planning to present), no relevant financial activities outside the submitted work (over the 3 years  
22  
23 prior to submission), and no other relationships or activities that readers could perceive to have  
24  
25 influenced, or that give the appearance of potentially influencing what is written in the submitted  
26  
27 work (based on all relationships that were present during the 3 years prior to submission) for any  
28  
29  
30  
31  
32 of the co-authors.

33  
34  
35  
36  
37 Drs. Nadia Khan and Calvin Ke take full responsibility for the work as a whole, including the  
38  
39 study design, access to data, and the decision to submit and publish the manuscript.

40  
41  
42  
43 **Data Sharing Statement:** all datasets are available through Population Data BC, subject to  
44  
45 approval by relevant data stewards at the BC Ministry of Health.  
46  
47  
48

## 49 50 51 52 53 **References** 54 55 56 57 58 59 60

- 1  
2  
3 1. The ACCORD Study Group. [ACCORD-BP] Effects of Intensive Blood-Pressure Control  
4 in Type 2 Diabetes Mellitus. *N Engl J Med*. 2010;362(17):1575–85.
- 5  
6  
7 2. American Diabetes Association. Standards of Medical Care in Diabetes--2013. *Diabetes*  
8 *Care*. 2012 Dec 20;36(Supplement\_1):S11–66.
- 9  
10 3. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian  
11 Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management  
12 of Diabetes in Canada. *Can J Diabetes*. 2013 Apr;37(Suppl 1):S1–212.
- 13  
14 4. Chatterton H, Younger T, Fischer A, Khunti K. Risk identification and interventions to  
15 prevent type 2 diabetes in adults at high risk: summary of NICE guidance. *BMJ*.  
16 2012;345:e4624.
- 17  
18 5. Asian-Pacific Type 2 Diabetes Policy Group. International Diabetes Federation Western  
19 Pacific Region Type 2 Diabetes Practical Targets and Treatment guidelines [Internet].  
20 Melbourne, Australia: International Diabetes Institute; 2005 [cited 2013 Sep 26]. Available  
21 from: <http://www.idf.org/idf-wpr-type-2-diabetes-practical-targets-and-treatments>
- 22  
23 6. Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in  
24 hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and  
25 lisinopril. *JAMA*. 2005 Apr 6;293(13):1595–608.
- 26  
27 7. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical  
28 outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose  
29 concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to  
30 Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005 Jun 27;165(12):1401–9.
- 31  
32 8. Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better  
33 to calciumblockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers?  
34 Asystematic review. *BMC Med*. 2013 May 30;11(1):141.
- 35  
36 9. Mahmoudpour SH, Leusink M, Putten LVD, Terreehorst I, Asselbergs FW, De Boer A, et  
37 al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic  
38 review and meta-analysis. *Pharmacogenomics*. 2013 Feb;14(3):249–60.
- 39  
40 10. Gupta AK. Racial Differences in Response to Antihypertensive Therapy: Does One Size  
41 Fits All? *Int J Prev Med*. 2010;1(4):217–9.
- 42  
43 11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk  
44 of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ*.  
45 1998 Sep 12;317(7160):713–20.
- 46  
47 12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of  
48 nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-  
49 insulin-dependent diabetes and hypertension. *N Engl J Med*. 1998;338(10):645–652.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on  
4 cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the  
5 HOPE study and MICRO-HOPE substudy. *The Lancet*. 2000 Jan 22;355(9200):253–9.  
6  
7
- 8 14. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al.  
9 [ONTARGET] Telmisartan, ramipril, or both in patients at high risk for vascular events. *N*  
10 *Engl J Med*. 2008 Apr 10;358(15):1547–59.  
11
- 12 15. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al. Telmisartan to  
13 Prevent Recurrent Stroke and Cardiovascular Events. *N Engl J Med*. 2008 Sep  
14 18;359(12):1225–37.  
15  
16
- 17 16. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. [SHEP]  
18 Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated  
19 systolic hypertension with and without diabetes. *Am J Cardiol*. 2005 Jan 1;95(1):29–35.  
20  
21
- 22 17. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.  
23 Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes.  
24 *J Am Coll Cardiol*. 2010 Jun 29;56(1):77–85.  
25
- 26 18. International Diabetes Federation. IDF Diabetes Atlas [Internet]. International Diabetes  
27 Atlas; 2012 [cited 2013 Jun 19]. Available from: <http://www.idf.org/diabetesatlas/5e/>  
28
- 29 19. Brewster LM, Montfrans GA van, Oehlers GP, Seedat YK. Systematic review:  
30 antihypertensive drug therapy in patients of African and South Asian ethnicity. *Intern*  
31 *Emerg Med*. 2016 Apr 1;11(3):355–74.  
32  
33
- 34 20. BC Ministry of Health Data Stewardship Committee, BC Vital Statistics Agency.  
35 Consolidation File (MSP Registration & Premium Billing); Discharge Abstracts Database  
36 (Hospital Separations) and Medical Services Plan (MSP) Payment Information File;  
37 PharmaNet; Vital Statistics Deaths [Internet]. Population Data BC; BC Ministry of Health;  
38 2012 2014. Available from: <http://www.popdata.bc.ca/data>  
39  
40
- 41 21. Lindsay C. The South Asian Community in Canada [Internet]. Ottawa: Social and  
42 Aboriginal Statistics Division, Statistics Canada; 2001 [cited 2013 May 9]. (Profiles of  
43 Ethnic Communities in Canada). Report No.: 89–621–XIE. Available from:  
44 <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2007006-eng.htm#4>  
45  
46
- 47 22. Lindsay C. The Chinese Community in Canada [Internet]. Ottawa: Social and Aboriginal  
48 Statistics Division, Statistics Canada; 2001 [cited 2013 May 9]. (Profiles of Ethnic  
49 Communities in Canada). Report No.: 89–621–XIE. Available from:  
50 <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2006001-eng.htm>  
51  
52
- 53 23. Chong E, Wang H, King-Shier KM, Quan H, Rabi DM, Khan NA. Prescribing patterns and  
54 adherence to medication among South-Asian, Chinese and white people with type 2  
55 diabetes mellitus: a population-based cohort study. *Diabet Med J Br Diabet Assoc*. 2014  
56 Dec;31(12):1586–93.  
57  
58  
59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
24. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. *The Lancet*. 2007 Mar;369(9563):750–6.
25. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. *Diabetes Res Clin Pract*. 2010 Aug;89(2):189–95.
26. Khan NA, Wang H, Anand S, Jin Y, Campbell NRC, Pilote L, et al. Ethnicity and sex affect diabetes incidence and outcomes. *Diabetes Care*. 2011 Jan;34(1):96–101.
27. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. *BMC Med Res Methodol*. 2010 May 15;10:42.
28. Milan A, Maheux H, Chui T. A portrait of couples in mixed unions. *Can Soc Trends* [Internet]. 2010 Apr 20 [cited 2013 May 9];Summer 2010(89). Available from: <http://www.statcan.gc.ca/pub/11-008-x/2010001/article/11143-eng.htm>
29. Government of Canada SC. Tables by subject: Ethnic diversity and immigration [Internet]. 2013 [cited 2013 Feb 27]. Available from: [http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/ind01/l2\\_30000-eng.htm](http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/ind01/l2_30000-eng.htm)
30. Hanley GE, Morgan S. On the validity of area-based income measures to proxy household income. *BMC Health Serv Res*. 2008 Apr 10;8:79.
31. Monami M, Lambertucci L, Lamanna C, Lotti E, Marsili A, Masotti G, et al. Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. *Aging Clin Exp Res*. 2007 Dec;19(6):492–6.
32. Brunner NW, Ramanathan K, Wang H, Quan H, Khan NA. Effectiveness of Statin Prescribing on Reducing Mortality in South Asian, Chinese, and White Patients With Diabetes. *Can J Cardiol*. 2013 Aug;29(8):920–6.
33. Mansournia MA, Altman DG. Inverse probability weighting. *BMJ*. 2016 Jan 15;352:i189.
34. Mansournia MA, Danaei G, Forouzanfar MH, Mahmoodi M, Jamali M, Mansournia N, et al. Effect of Physical Activity on Functional Performance and Knee Pain in Patients With Osteoarthritis: Analysis With Marginal Structural Models. *Epidemiology*. 2012 Jul;23(4):631–40.
35. Gharibzadeh S, Mohammad K, Rahimiforushani A, Amouzegar A, Mansournia MA. Standardization as a Tool for Causal Inference in Medical Research. *Arch Iran Med*. 2016 Sep;19(9):666–70.
36. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med*. 2014 Mar 30;33(7):1242–58.

- 1  
2  
3 37. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for  
4 standardizing adherence measures derived from administrative claims data among diabetic  
5 patients. *Med Care*. 2008;46(11):1125–1133.  
6  
7
- 8 38. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al.  
9 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan  
10 Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial  
11 against atenolol. *The Lancet*. 2002 Mar 23;359(9311):1004–10.  
12
- 13 39. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K. Antihypertensive medication  
14 prescribing in 27,822 elderly Canadians with diabetes over the past decade. *Diabetes Care*.  
15 2006;29(4):836–841.  
16  
17
- 18 40. Khan NA, Grubisic M, Hemmelgarn B, Humphries K, King KM, Quan H. Outcomes After  
19 Acute Myocardial Infarction in South Asian, Chinese, and White Patients. *Circulation*.  
20 2010 Oct 19;122(16):1570–7.  
21
- 22 41. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for  
23 public health. *Int J Epidemiol*. 2009 Jun 1;38(3):791–813.  
24  
25
- 26 42. Yip VLM, Pirmohamed M. Expanding Role of Pharmacogenomics in the Management of  
27 Cardiovascular Disorders. *Am J Cardiovasc Drugs*. 2013 Jun;13(3):151–62.  
28  
29
- 30 43. Tsoi KKF, Wong MCS, Tam WWS, Hirai HW, Lao XQ, Wang HHX, et al. Cardiovascular  
31 mortality in hypertensive patients newly prescribed perindopril vs. lisinopril: A 5-year  
32 cohort study of 15,622 Chinese subjects. *Int J Cardiol*. 2014 Oct 20;176(3):703–9.  
33
- 34 44. Wang L, Kwak M-J. Immigration, barriers to healthcare and transnational ties: A case study  
35 of South Korean immigrants in Toronto, Canada. *Soc Sci Med* 1982. 2015 May;133:340–8.  
36  
37
- 38 45. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, et al. Do  
39 observational studies using propensity score methods agree with randomized trials? A  
40 systematic comparison of studies on acute coronary syndromes. *Eur Heart J*. 2012 Aug  
41 1;33(15):1893–901.  
42
- 43 46. Hernán MA. The Hazards of Hazard Ratios. *Epidemiol Camb Mass*. 2010 Jan;21(1):13–5.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Baseline characteristics among diabetes patients aged 35 years and older\*. Chi-square tests and analyses of variance showed statistically significant differences among the three groups ( $p < 0.0001$ ) for all baseline characteristics.

Characteristics	South Asian ( <i>n</i> =13 755)	Chinese ( <i>n</i> =22 871)	Other ( <i>n</i> =172 244)
Age, mean age (years) $\pm$ SD or %			
All patients	56.4 $\pm$ 12.6	59.2 $\pm$ 12.7	61.5 $\pm$ 12.8
35-49 years	33.2	24.7	18.8
50-64 years	39.8	43.1	42.0
65-79 years	23.2	25.3	29.5
$\geq$ 80 years	3.87	6.8	9.7
Women (%)	45.0	48.4	45.1
Income Quintile (%)			
1 <sup>st</sup> quintile (low)	25.6	27.4	21.2
2 <sup>nd</sup> quintile	32.2	23.4	20.7
3 <sup>rd</sup> quintile	20.4	20.2	20.0
4 <sup>th</sup> quintile	12.3	14.4	19.3
5th quintile (high)	8.8	13.4	17.5
Unknown	0.7	1.0	1.2
Comorbidities (%)			
Hypertension	42.0	44.0	47.9
Myocardial infarction	2.2	1.0	2.6
Congestive heart failure	3.0	2.1	5.3
Peripheral vascular disease	0.6	1.3	2.0
Cancer	2.8	3.8	6.3
Cerebrovascular disease	1.8	2.0	3.2
Chronic pulmonary disease	11.2	6.4	11.4
Renal disease	2.2	2.3	3.1
Medications prescribed at baseline <i>n</i> (%)			
ACEi	15.7	11.0	22.8
ARB	7.2	10.0	8.7
CCB	8.1	9.1	8.5
Diuretic	11.3	12.4	18.3
$\beta$ -blocker	9.5	8.4	13.3
Metformin	21.3	15.4	23.8
Sulfonylurea	3.8	2.6	3.5
Insulin	0.6	0.7	1.7
Statin	24.2	20.8	26.9
Medications prescribed after 1 year of diabetes diagnosis <i>n</i> (%)			
ACEi	26.1	17.8	33.5
ARB	12.6	16.3	13.7
CCB	12.6	13.9	12.8
Diuretic	18.7	18.6	27.0



Any ACEi, ARB, CCB, diuretic**	55.2	47.7	64.9
--------------------------------	------	------	------

\*All p-values comparing the 3 ethnic groups were less than 0.001

\*\*Abbreviations: SD = standard deviation, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 2** Association between antihypertensive medications and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian		Chinese		Other	
	HR	p-value	HR	p-value	HR	p-value
ACEi	0.91 (0.71-1.17)	0.47	0.84 (0.69-1.03)	0.09	0.88 (0.84-0.91)	<0.0001
ARB	0.88 (0.63-1.25)	0.48	0.64 (0.50-0.82)	0.0004	0.69 (0.64-0.74)	<0.0001
CCB	1.25 (0.93-1.68)	0.14	0.94 (0.77-1.15)	0.56	1.00 (0.94-1.05)	0.89
Diuretic	0.83 (0.61-1.12)	0.22	0.77 (0.62-0.96)	0.02	0.66 (0.63-0.69)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 3** Association between medication adherence and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian (n=9404)	p-value	Chinese (n=13 173)	p-value	Other (n=124 594)	p-value
Any ACEi, ARB, CCB, diuretic <sup>†</sup>	1.11 (0.71-1.73)	0.65	1.29 (0.83-2.01)	0.25	0.79 (0.72-0.86)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

<sup>†</sup> Hazard ratios for patients prescribed any antihypertensive (ACEi, ARB, CCB, diuretic) with moderate or high adherence compared to low adherence

1  
2  
3 Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB =  
4 angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker  
5  
6  
7


8 **Figure 1** Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and  
9 diuretics (“DIU”) according to ethnicity: (A) South Asian; (B) Chinese; (C) Other  
10

11 *(see Figure 1A, 1B, 1C files attached separately)*  
12

13  
14 \* Cox proportional hazards models were weighted using a propensity score model by the IPTW  
15 method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin,  
16 ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription  
17 within 1 month before or after diagnosis.  
18


19 Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor  
20 blocker, CCB = dihydropyridine calcium channel blocker  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics ("DIU") according to ethnicity: (A) South Asian; (B) Chinese; (C) Other<sup>†</sup> \* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.<sup>†</sup> Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

132x146mm (300 x 300 DPI)



Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics ("DIU") according to ethnicity: (A) South Asian; (B) Chinese; (C) Other<sup>†</sup> \* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.<sup>†</sup> Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

132x146mm (300 x 300 DPI)



Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics ("DIU") according to ethnicity: (A) South Asian; (B) Chinese; (C) Other† \* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.† Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

132x146mm (300 x 300 DPI)

## Appendix I. Additional Tables

**Supplemental Table S1** Mean and standard deviation of stabilized inverse probability weights

Ethnicity	Estimated Weights	
	Mean	Standard Deviation
South Asian	0.98	0.42
Chinese	0.98	0.33
Other	0.98	0.46

**Supplemental Table S2** Statistical power for each drug by ethnicity calculated using Fisher's exact method (two-sided  $\alpha=0.05$ ), specifying actual sample sizes, the treatment and event rates observed, and the risk reduction observed in major clinical trials cited in the manuscript. The same expected risk reduction was used for CCB and diuretics because the ALLHAT study utilized an active comparator instead of a placebo control, showing no significant difference between effectiveness of amlodipine and chlorthalidone in reducing all-cause mortality.

	Expected Risk Reduction	Power		
		South Asian	Chinese	Other
ACEi	24%	66.9%	70.6%	>99.9%
ARB	39%	74.3%	98.6%	>99.9%
CCB	20%	23.0%	45.4%	>99.9%
Diuretic	20%	30.9%	55.5%	>99.9%

### References:

1. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *The Lancet*. 2000 Jan 22;355(9200):253–9.
2. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547–59.
3. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005 Jun 27;165(12):1401–9.
4. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. *The American Journal of Cardiology*. 2005 Jan 1;95(1):29–35.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract <b>[title page 1 and abstract page 2]</b> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>[abstract page 2]</b>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>[introduction page 4]</b>
Objectives	3	State specific objectives, including any prespecified hypotheses <b>[introduction page 5]</b>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper <b>[methods page 5]</b>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>[methods pages 5-7]</b>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>[methods pages 5-8]</b> <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <b>[methods page 9]</b> <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>[methods pages 7-9]</b>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>[methods pages 8-9]</b>
Bias	9	Describe any efforts to address potential sources of bias <b>[methods page 9]</b>
Study size	10	Explain how the study size was arrived at <b>[methods page 6]</b>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>[methods page 9]</b>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>[methods pages 9-10]</b> (b) Describe any methods used to examine subgroups and interactions N/A (c) Explain how missing data were addressed N/A (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed N/A <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses <b>[methods page 9]</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Continued on next page

For peer review only

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [ <b>results page 10</b> ] (b) Give reasons for non-participation at each stage <b>N/A</b> (c) Consider use of a flow diagram <b>N/A</b>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [ <b>page 21 Table 1</b> ] (b) Indicate number of participants with missing data for each variable of interest [ <b>page 21 Table 1</b> ] (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) [ <b>results page 11</b> ]
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time [ <b>results page 11</b> ] <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [ <b>page 22 Table 2</b> ] (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [ <b>page 22 Table 3</b> ]

**Discussion**

Key results	18	Summarise key results with reference to study objectives [ <b>Discussion page 12</b> ]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [ <b>Discussion page 15</b> ]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [ <b>Discussion pages 12-15</b> ]
Generalisability	21	Discuss the generalisability (external validity) of the study results [ <b>Discussion page 15</b> ]

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [ <b>page 16</b> ]
---------	----	--

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Is Cardiovascular Risk Reduction Therapy Effective in South Asian, Chinese, and Other Patients with Diabetes? A Population-Based Cohort Study from Canada

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013808.R2
Article Type:	Research
Date Submitted by the Author:	23-May-2017
Complete List of Authors:	Ke, Calvin; University of Toronto Morgan, Steve; University of British Columbia, School of Population and Public Health Smolina, Kate; University of British Columbia, School of Population and Public Health Gasevic, Danijela; University of Edinburgh, Qian, Hong; Center for Health Evaluation and Outcomes Sciences, Medicine Khan, Nadia; University of British Columbia, Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Hypertension < CARDIOLOGY

SCHOLARONE™  
Manuscripts

Only



1  
2  
3 **Is Cardiovascular Risk Reduction Therapy Effective in South Asian, Chinese, and Other**  
4  
5 **Patients with Diabetes? A Population-Based Cohort Study from Canada**  
6  
7  
8  
9

10 **Running Title: Cardiovascular Risk Reduction in Diabetes**  
11  
12  
13

14  
15 Authors: Calvin H Ke MD (1), Steve Morgan PhD (2), Kate Smolina PhD (2), Danijela Gasevic  
16  
17 MD, PhD (3), Hong Qian MSc (4), Nadia A Khan MD MSc (1, 4)  
18  
19

20  
21  
22 (1) Department of Medicine, University of British Columbia, Vancouver, British Columbia,  
23 Canada

24 (2) School of Population and Public Health, University of British Columbia, Vancouver,  
25 British Columbia, Canada

26 (3) Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK

27 (4) Center for Health Evaluation and Outcomes Sciences, University of British Columbia,  
28 Vancouver, British Columbia, Canada  
29  
30  
31

32  
33 Corresponding Author:  
34 Nadia Khan MD MSc  
35 620B, 1081 Burrard Street,  
36 Vancouver, BC  
37 P:604 682-2344  
38 F:604 806-8005  
39 nakhanubc@gmail.com  
40  
41  
42

43 Abstract: 265 words

44 Manuscript: 3778 words

45  
46  
47  
48 Tables & Figures: 4  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** Guidelines recommend angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB) and diuretics in all patients with diabetes mellitus. However, the effectiveness of these agents in South Asian and Chinese populations is unknown. We sought to determine whether ACEi, ARB, CCB, and diuretics are associated with reduced mortality in South Asian, Chinese, and other patients with diabetes.

**Design:** Population-based cohort study using administrative health databases

**Setting:** Province of British Columbia, Canada (2006-2013)

**Participants:** Patients aged  $\geq 35$  years with incident diabetes

**Primary and secondary outcome measures:** Primary outcome was all-cause mortality for each medication class compared to untreated patients within each ethnicity. Treatment effect was assessed using inverse probability of treatment weighted Cox proportional hazards models. Medication adherence effect on mortality was also evaluated.

**Results:** 208,870 patients (13,755 South Asian, 22,871 Chinese, 172,244 other Canadian) were included. ACEi reduced mortality in other patients (HR=0.88, 0.84-0.91), but power was insufficient to evaluate for benefit in Chinese and South Asian patients. ARB and diuretics reduced mortality in Chinese (ARB HR=0.64, 0.50-0.82; diuretics HR=0.77, 0.62-0.96) and other patients (ARB HR=0.69, 0.64-0.74; diuretics HR=0.66, 0.63-0.69) compared with untreated patients. No mortality benefit was observed among South Asians for any drug class or for CCB among all ethnicities. Higher medication adherence was associated with lower mortality for other patients only (HR=0.79, 0.72-0.86).

1  
2  
3 **Conclusions:** Effectiveness of cardiovascular risk reduction therapy on mortality varies  
4  
5 considerably by ethnicity. Further study is needed to evaluate the mortality benefit of  
6  
7 antihypertensive agents in South Asians. Inclusion of these ethnic groups in future clinical trials  
8  
9 is essential to examine for differential responses.  
10  
11

12  
13  
14  
15 Strengths and limitations of this study:  
16

- 17 • This study addresses a substantial gap in the literature regarding long-term effectiveness  
18 of commonly used antihypertensive drug classes among diabetes patients of South Asian  
19 and Chinese descent  
20  
21
  - 22 • The analysis is conducted on a large, population-based data set including significant  
23 numbers of people of different ethnicities in Canada, allowing for measurement of real-  
24 world effects on mortality  
25  
26
  - 27 • Limitations include possible residual confounding due to unmeasured variables  
28  
29  
30  
31  
32
- 33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Pharmacologic treatment of hypertension in patients with type 2 diabetes mellitus (diabetes) is associated with significantly reduced mortality (1). International guidelines recommend routinely using antihypertensive medications to reduce cardiovascular risk in all diabetes patients, including those of Asian ethnicity (2–5). However, most trials of cardiovascular risk reduction therapy in patients with diabetes occurred in western populations.

Response to these therapies can be affected by ethnicity. ACE inhibitors (ACEi) were found to be less effective in reducing mortality and cardiovascular events among Black patients with hypertension and diabetes compared with other antihypertensive agents (6–8). Several studies also reported higher risk of ACEi-induced cough in Chinese patients suggesting that there may be some underlying differences in response to these medications (9). Others reported that South Asians may have increased sympathetic activity, possibly causing differing responses to antihypertensive classes (10). An analysis in South Asian and Chinese patients with newly diagnosed diabetes found significant mortality reductions associated with statin use (10). However, similar analyses are currently lacking for antihypertensive agents.

The benefit of ACEi in reducing cardiovascular risk in diabetes was established in multiple large randomized-control trials of western patients, with 24% reduction in the secondary outcome of total mortality seen in the HOPE study (11–13). These benefits were similar to angiotensin receptor blockers (ARB) based on the ONTARGET study subset of diabetes patients (14). However, the PROfESS trial included 18% of patients of Chinese ethnicity and 8.4% of South Asian ethnicity, found no benefit of telmisartan in reducing major cardiovascular events (15).

1  
2  
3 Additionally, major randomized trials examining thiazide and thiazide-like diuretics ((SHEP (16),  
4 ALLHAT (7)), CCB (ALLHAT (7)) and CCB-based combinations (ACCOMPLISH (17)) were  
5  
6 conducted in predominantly western populations.  
7  
8  
9

10  
11  
12 The burden of diabetes in South Asian and Chinese populations is tremendous, with these ethnic  
13 groups representing 62% of all adults with diabetes globally (18). In this context, the paucity of  
14 large studies specifically comparing long-term effectiveness of major antihypertensive drug  
15 classes in these ethnicities is concerning (19). With the existing, widespread use of these  
16 medications, such studies are unlikely to be conducted in the near future. In an effort to fill the  
17 information gap, we conducted a population-based cohort study to determine whether ACEi,  
18 ARB, dihydropyridine CCB, and diuretics are effective in reducing all-cause mortality in a  
19 population cohort of South Asian (originating from Pakistan, India, or Bangladesh), Chinese  
20 (originating from China, Taiwan, or Hong Kong), and other patients with newly diagnosed  
21 diabetes.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Research Design and Methods**

### 40 41 42 43 *Study Overview*

44  
45  
46  
47  
48 We conducted an analysis using population-based administrative data of adults aged  $\geq 35$  years  
49 living in British Columbia, Canada with newly diagnosed diabetes between April 1, 2006 and  
50  
51 March 31, 2013.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Data Sources*

We used administrative data from British Columbia, Canada. We obtained de-identified linked health datasets through Population Data BC with approval of relevant data stewards and the University of British Columbia's Behavioural Research Ethics Board (20). All inferences, opinions, and conclusions drawn in this report are those of the authors, and do not reflect the opinions or policies of Population Data BC.

The databases covered all British Columbians except those whose prescription drug coverage fell under federal jurisdiction (i.e., military, veterans, inmates of federal penitentiaries, and status Indians living on reserves, approximately 4.0% of the total population). All residents included in our dataset are covered under British Columbia's universal, public health insurance program for medical and hospital care; and all are eligible for coverage under British Columbia's universal, public drug benefit plan, under which deductibles are set in relation to household income.

British Columbia has a total population of 4.6 million people, including approximately 210 400 South Asian and 373 800 Chinese people (21,22). Because the public health insurance program covers virtually all health encounters, data from physician billing claims can be used to identify diagnoses. We extracted International Classification of Diseases (ICD-9 and ICD-10) codes from physician claims including both inpatient and outpatient encounters. Outpatient billing data include a single diagnosis for each encounter. Inpatient data include both primary (most responsible diagnosis) and secondary (comorbid conditions) diagnosis codes from hospital discharge abstracts (up to 25 codes for each encounter). Data on medication use were extracted

1  
2  
3 from PharmaNet, a provincial electronic database that contains a record of all dispensed  
4  
5 prescriptions from community pharmacies. The accuracy of this database against prescriptions is  
6  
7 estimated to be greater than 99% (23). Data on time of death were obtained from the vital  
8  
9 statistics database and reporting of all deaths in the province is mandatory.  
10  
11

### 12 13 14 15 *Study Population*

16  
17  
18  
19  
20 The study population was restricted to people with a new diagnosis of diabetes during the study  
21  
22 period. A new diagnosis of diabetes was defined as an ICD-9 or ICD-10 code for diabetes for at  
23  
24 least one hospital discharge abstract or two physician claims within 2 years (ICD-9-CM: 250.x;  
25  
26 ICD-10: E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, and E145). To  
27  
28 ensure that these cases were truly new diagnoses, we set a washout period of 3 years (i.e., no  
29  
30 physician claims for diabetes in the preceding 3 years). This algorithm is entirely based on  
31  
32 administrative billing data, and was previously validated against physician diagnosis of diabetes  
33  
34 in adults aged  $\geq 35$  years with sensitivity 92% and specificity 97% in identifying diagnoses of  
35  
36 diabetes in British Columbia (24–26). Index date was defined as the earliest contact with the  
37  
38 healthcare system with the diabetes diagnosis. Patients who died within 1 month of diabetes  
39  
40 diagnosis were excluded from the analysis.  
41  
42  
43  
44  
45  
46  
47

### 48 49 *Categorizing Ethnic Group*

50  
51  
52  
53 Because ethnicity is not routinely recorded in Canadian administrative health data, we used an  
54  
55 algorithm developed to identify surnames of South Asian and Chinese origin that has been  
56  
57  
58  
59  
60

1  
2  
3 validated for use in administrative data research by Shah et al. (27). Canadian census data show  
4 that 93% of South Asians and 90% of Chinese marry people of the same ethnic background,  
5  
6 minimizing the chance of misidentification due to mixed marriages (28). We labelled the  
7  
8 remaining population as “other.” In the province of British Columbia, the vast majority of this  
9  
10 group consists of individuals of European ancestry (>90%), with very few people of African  
11  
12 ancestry (<1%) (29).  
13  
14  
15  
16  
17  
18  
19

### 20 *Sociodemographics and Comorbid Conditions*

21  
22  
23  
24 We estimated socioeconomic status (SES) using income quintile. We estimated household  
25  
26 income based on a combination of household-specific and area-based income data (30). We also  
27  
28 included comorbidities from the Charlson comorbid conditions list (31). These conditions were  
29  
30 extracted from all inpatient and outpatient claims dating from up to 1 year prior to the index date.  
31  
32  
33  
34  
35

### 36 *Cardiovascular Risk Reduction Medications*

37  
38  
39  
40 Within each ethnicity, we classified study patients as either treated or untreated with each  
41  
42 antihypertensive medication class: ARB, ACEi, dihydropyridine CCB, and thiazide or thiazide-  
43  
44 type diuretics. We considered patients as treated with a medication if they received at least one  
45  
46 prescription within 1 year after index diagnosis, a time period used in other similar studies (32).  
47  
48  
49  
50  
51

### 52 *Outcome Measures*



1  
2  
3 Patients were followed for up to 4 years for the primary outcome measure, time to death from  
4 any cause. Risk was determined for South Asian, Chinese, and other patients treated on each  
5 medication as compared to untreated patients (regardless of other antihypertensive use) within  
6 each ethnicity as a baseline.  
7  
8  
9  
10  
11

### 12 13 14 15 *Statistical Analysis* 16

17  
18  
19  
20 Baseline characteristics for each ethnic group were summarized and compared among the groups  
21 using the Chi square test for categorical variables and analysis of variance for continuous  
22 variables. We constructed inverse probability of treatment weighted (IPTW) Cox proportional  
23 hazards models for the treatment effect on mortality (33,34). This method is aimed at minimizing  
24 effects of confounding by indication (35). The weight was based on a propensity score of having  
25 treatment, estimated from a multivariable logistic regression model with receiving treatment as a  
26 binary outcome variable and age, gender, SES, Charlson comorbidities, and baseline use of other  
27 medications as independent variables. In particular, the weight for each subject was computed by  
28 taking the inverse probability of receiving treatment that the subject received and stabilized by  
29 multiplying marginal probability of the actual treatment received (36). Means and standard  
30 deviations of the weights were assessed to verify the positivity assumption. Schoenfeld residuals  
31 were explored to examine the proportional hazards assumption. Cumulative incidence of death  
32 was also visualized for the weighted sample. Use of other medications (insulin, use of other  
33 antihypertensive agents and statins) at baseline was defined as a prescription recorded within 1  
34 month before or after diagnosis. The data were censored at the end of the 4-year observation  
35 period or at death, whichever came first.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Statistical power for each drug by ethnicity was calculated using the log-rank test, specifying  
4 actual sample sizes, allocation ratio, treatment and event rates observed, and hazard ratio as  
5 derived from the risk reduction observed in major clinical trials (Supplemental Table S1).  
6  
7

8  
9  
10 Estimated power was >99.9% for the other group (all classes) and for ARB in Chinese, >80% for  
11 ARB in South Asians and ACEi in Chinese patients, and <80% for the remaining categories.  
12

13  
14 In a sensitivity analysis to account for effects of differential drug exposure (including treatment  
15 cessation or switching between classes), we evaluated the association of level of medication  
16 adherence with mortality among patients who were treated with at least one of the four study  
17 medication classes. We constructed the IPTW Cox proportional hazards models to compare  
18 among the medication adherence levels. In particular, the adherence of each medication was  
19 measured over 1 year since the first prescription using proportion of days covered (PDC), which  
20 has a high predictive validity for hospitalization episodes (37). The PDC is defined as [(number  
21 of days supply of medication in the index period)/(number of days in the study period)] × 100.  
22  
23

24  
25 The mean PDC across the four classes was calculated and classified into three levels with PDC ≥  
26 0.80 classified as high adherence,  $0.50 \leq \text{PDC} < 0.80$  as moderate adherence, and PDC < 0.50 as  
27 low adherence.  
28  
29

30  
31  
32 All *p* values presented are 2-tailed, and a value of less than 0.05 was considered significant for  
33 all computations. Analyses were performed with SAS version 9.4 (SAS Institute Inc.).  
34  
35

## 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 **Results**

### 52 53 54 55 *Baseline Characteristics and Prescribing*

56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 There were 208 870 patients (13 755 South Asian, 22 871 Chinese, 172 244 other) included in  
7  
8 the analysis (Table 1). Most patients were elderly with South Asian patients being younger than  
9  
10 the other groups at time of diagnosis. South Asian and Chinese patients were more likely than  
11  
12 other patients to be in the 2 lowest socioeconomic quintiles. Hypertension was present in almost  
13  
14 half of patients across all ethnicities (42% South Asian, 44% Chinese, 48% other). The  
15  
16 prevalence of comorbid conditions was low in this cohort with South Asian and Chinese patients  
17  
18 having generally a lower prevalence of conditions compared with others, including myocardial  
19  
20 infarction, congestive heart failure, peripheral vascular disease, and cerebrovascular disease.  
21  
22  
23  
24  
25  
26

27 Other patients were the most likely to be prescribed antihypertensive agents at baseline, with the  
28  
29 most frequently prescribed classes being ACEi (23%) and diuretics (18%). South Asians were  
30  
31 also likely to be prescribed with ACEi (16%) and diuretics (11%). Chinese patients had a more  
32  
33 equal distribution among ACEi, ARB, CCB, and diuretic prescriptions (9.1-12%). By the end of  
34  
35 one year since initial diabetes diagnosis, almost two-thirds of other patients were prescribed at  
36  
37 least one antihypertensive agent, with a lower proportion in South Asian and Chinese patients.  
38  
39 The most frequently prescribed class of antihypertensive agent by this time was ACEi (26%  
40  
41 South Asians, 18% Chinese, 34% other), followed by diuretics (19% South Asians, 19% Chinese,  
42  
43 27% other).  
44  
45  
46  
47  
48  
49

#### 50 *Mortality*

51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Overall, 6.5% of patients ( $n=355$  for South Asian,  $n=679$  for Chinese,  $n=11480$  for other) died  
4 during the follow up period (median 3 years; Figure 1). Among other patients, ACEi (HR=0.88,  
5 0.84-0.91; Table 2), ARB (HR=0.69, 0.64-0.74) and diuretics (HR=0.66, 0.63-0.69) were  
6 associated with substantial reductions in all-cause mortality, with minimal association observed  
7 with CCB (HR=1.00, 0.94-1.05). Consistent with the positivity assumption, the means of the  
8 stabilized weights were close to one with low standard deviations (Supplemental Table S2).  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Similarly, among Chinese patients, ARB (HR=0.64, 0.50-0.82) and diuretics (HR=0.77, 0.62-  
21 0.96) were associated with significant mortality reduction. There was a non-significant trend  
22 towards benefit with ACEi (HR=0.84, 0.69-1.03), but there was no significant association  
23 observed with CCB.  
24  
25  
26  
27  
28  
29  
30  
31

32 In South Asian patients, no statistically significant mortality benefits were observed with ACEi  
33 (HR=0.91, 0.71-1.17), ARB (HR=0.88, 0.63-1.25), CCB (HR=1.25, 0.93-1.68), or diuretics  
34 (HR=0.83, 0.61-1.12).  
35  
36  
37  
38  
39  
40

41 In our sensitivity analysis that included level of drug exposure in all drug classes, a moderate to  
42 high adherence to the 4 antihypertensive classes was associated with lower mortality among  
43 other patients compared to low adherence (Table 3). However, high or moderate adherence was  
44 not associated with reduced mortality compared with low adherence of antihypertensive  
45 medications among Chinese and South Asian patients. There was insufficient power to analyze  
46 the effects of high versus low adherence, or adherence within single medication classes.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

Overall, we observed substantial ethnic differences in the association between cardiovascular risk reduction therapies and mortality in patients with diabetes. Mortality reduction associated with treatment with ARB, diuretics and a trend towards mortality benefit with ACEi were observed Chinese patients. However, no significant associations with mortality and cardiovascular risk reduction therapy were seen in South Asians for any drug class.

It is difficult to directly compare our findings with those of previous major clinical trials due to differences in study methodology, inability to directly compare the magnitude of hazards ratios and relative risks, and due to the specification of all-cause mortality as a non-primary outcome in most of these trials. Nevertheless, the associations we observed in the other population are generally consistent in direction with results from major clinical trials in patients with diabetes (13,14, 33). For ACEi, the benefit we observed (HR=0.88, 0.84-0.91) is consistent with findings reported in the HOPE study (total mortality relative risk 0.76, 0.63-0.92) that compared ramipril to placebo in patients with diabetes and an additional cardiovascular risk factor (13). The mortality reduction for ARB (HR=0.69, 0.64-0.74) is similar to that seen in the LIFE study (relative risk 0.61, 0.45-0.84), comparing losartan to atenolol (38).

Among Chinese patients, we observed generally similar mortality reductions associated with ACEi (HR=0.84, 0.69-1.03) and ARB (HR=0.64, 0.50-0.82) use, although the benefit of ACEi did not reach statistical significance. Notably, adherence to ACEi among Chinese patients (52%) compared to ARB (72%) is reported to be lower than other patients, and this difference may have

1  
2  
3 attenuated the association with ACEi (23). Nevertheless, our results provide new evidence of  
4 these agents in a real world population extending the findings of the ONTARGET (14) study,  
5 that included 14% of patients of Asian ethnicity. Given these findings, it is particularly important  
6 to emphasize the increased use of these medications, particularly given the gaps in prescription  
7 filling observed among Chinese and South Asian patients, who had lower than expected rates of  
8 renin-angiotensin system antagonist prescription.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Diuretics were associated with reduced mortality in Chinese. The effects observed (Chinese  
21 HR=0.77, 0.62-0.96) are largely consistent with those reported in the placebo-controlled SHEP  
22 trial (16) diabetes subgroup (HR 0.80, 0.68-0.95). The present findings are the first to our  
23 knowledge to evaluate thiazide and thiazide like diuretics to Chinese patients with diabetes.  
24  
25  
26  
27  
28  
29  
30  
31

32 We did not observe substantial benefits of CCB in any ethnic category. This result was  
33 unexpected given the findings of the ALLHAT study, that showed that CCB were equivalent to  
34 ACEi and diuretics as first-line antihypertensive agents in diabetes (7). These findings may  
35 reflect the trend that CCB are decreasingly likely to be used as initial antihypertensive therapy  
36 compared to ACEi and diuretics in Canada (39). This trend is in accordance with guidelines  
37 promoting CCB as an add-on agent given the ACCOMPLISH trial findings (17). Patients in the  
38 CCB group may have had more severe hypertension requiring more than one agent, thereby  
39 causing confounding by indication. Moreover, the comparison group in our study likely included  
40 patients treated with other agents such as ACEi, ARB, and diuretics, leading to an attenuation of  
41 observed association. It is also possible that the real-world effect size varies from that observed  
42 in randomized control trials (RCTs) due to rigid selection criteria and selection bias. Further  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 research is required to clarify the benefit of CCB, especially in South Asian and Chinese  
4  
5  
6 populations.  
7  
8  
9

10 None of the drug classes were associated with any statistically significant mortality benefits  
11 among South Asians. A major reason for the lack of findings could have been a lack of power  
12 (Supplemental Table S1) given low event rates ( $n=355$  events, 2.6% event rate in South Asians;  
13  $n=679$  events, 3.0% in Chinese) and low prescription filling rates in this cohort. The lower rate  
14 of mortality events is consistent with evidence in our population demonstrating a lower rate of  
15 mortality following myocardial infarction, uniquely among South Asians (40). Moreover, the  
16 South Asian cohort had the youngest age distribution, and this could have led to relatively fewer  
17 mortality events and weaker associations particularly with diuretics, which may be more  
18 effective in older patients. It is conceivable that the association may also have been attenuated by  
19 additional factors such as cultural dietary practices (e.g. salt intake (41)) and pharmacogenetic  
20 influences. For instance, ACE gene insertion/deletion polymorphisms affect serum levels of  
21 ACEi, although a long-term effect on cardiovascular outcomes has yet to be demonstrated (42).  
22 Pharmacogenetic differences may also lead to heterogeneous responses to antihypertensive  
23 agents within the same class (43). With these considerations in mind, further research is required  
24 to confirm the effectiveness and magnitude of mortality benefit of cardiovascular risk reduction  
25 therapy in South Asians.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 The lack of significant associations among South Asians may also relate to poor medication  
51 adherence and reduced drug exposure. Although we performed a sensitivity analysis using drug  
52 adherence to evaluate whether drug discontinuation, switching between classes, or decreased  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 adherence may have affected our results, only in other patients was a significant mortality  
4  
5 reduction seen in those with moderate or high adherence. No significant associations were  
6  
7 observed for South Asian and Chinese patients. The lack of adherence effects may be related to  
8  
9 inadequate power to detect smaller treatment related effect size in these groups. Another  
10  
11 possibility is that some of these patients could have switched from one medication class to  
12  
13 another, thus attenuating the negative effects of being unexposed to the initial medication (for  
14  
15 example, switching from ACEi to ARB in Chinese patients due to cough). South Asian and  
16  
17 Chinese patients may also import antihypertensive medications from out of country, limiting our  
18  
19 ability to detect treatment differences (44). In the context of these limitations, more studies are  
20  
21 required to evaluate the interaction between medication adherence and antihypertensive therapies  
22  
23 in South Asian and Chinese patients.  
24  
25  
26  
27  
28  
29  
30  
31

32 Our large population-based observational study allowed for measurement of real-world mortality  
33  
34 differences, minimizing outcome misclassification and with virtually no loss to follow-up in the  
35  
36 context of Canada's universal healthcare system. Although observational studies of this nature  
37  
38 have been shown to generally correlate with randomized control trials (45), we recognize that  
39  
40 our cohort had lower prevalence of comorbid conditions compared to the more high-risk  
41  
42 populations included in clinical trials. Thus, it is possible that a mortality benefit for ACEi and  
43  
44 other cardiovascular risk reduction therapies may indeed exist among the subset of high-risk  
45  
46 South Asian (and Chinese) patients that was not captured in this study. Additional studies with a  
47  
48 larger sample size (given the relative lack of power in the South Asian cohort) or with a higher-  
49  
50 risk cohort would be required to evaluate this possibility, especially considering the Canadian  
51  
52 recommendation that ACEi or ARB be used for all diabetes patients over age 55 years—even in  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 the absence of end-organ damage or hypertension (4). To ensure that the results are generalizable  
4 to other real-world populations, more studies in other countries with different practice patterns  
5 and population compositions are required to improve external validity. We were also unable to  
6  
7  
8 assess for the additional benefits of combination therapies due to sample size considerations,  
9  
10 although this likely would not have explained the lack of associations observed in the Asian  
11  
12 cohorts. Further studies are required to assess these effects specifically in South Asian and  
13  
14 Chinese populations with diabetes (46). Moreover, the IPTW can be used to estimate exposure  
15  
16 effects adjusted for measured confounders only. However, there could have been residual  
17  
18 confounding due to unmeasured variables including hypertension severity and duration, age of  
19  
20 hypertension onset, treatment indication, treatment of previous cardiovascular comorbidities,  
21  
22 blood pressure levels, and hemoglobin A1C. Finally, there is a built-in selection bias that has  
23  
24 been described with use of hazard ratios (47). Given the limitations we have described, further  
25  
26 investigations using different methodologies are required to confirm the present findings.  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 Given the tremendous and increasing burden of diabetes in South Asian and Chinese patients  
37  
38 globally, there is an alarming paucity of large studies evaluating the effectiveness of routinely  
39  
40 used cardiovascular risk reduction therapies in these groups. ACEi, ARB, and diuretics are likely  
41  
42 effective among Chinese and other patients. Although it is likely that these drugs are effective in  
43  
44 high-risk diabetes patients across all ethnicities including South Asians, we were unable to  
45  
46 demonstrate this with our unselected, lower-risk population. Given that this study was not a  
47  
48 randomized controlled trial examining antihypertensive efficacy in these populations, these  
49  
50 findings should be interpreted with caution. More research is required to evaluate the  
51  
52 effectiveness of antihypertensive agents in South Asians, and to confirm the benefit of ACEi in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Chinese patients. Inclusion of these groups in future clinical trials is essential to examine for  
4  
5 differential response by ethnicity.  
6  
7  
8  
9  
10

### 11 12 13 14 15 16 17 **Author Contributions**

18  
19  
20 NAK, CK made substantial contributions to conception and design, SM and KS made substantial  
21  
22 contributions towards acquisition of data, all authors made substantial contribution to analysis of  
23  
24 data, all authors made substantial contribution towards interpretation of data, CK wrote the first  
25  
26 draft and all authors participated in revising it critically for important intellectual content; and all  
27  
28 authors give final approval of the version submitted.  
29  
30  
31  
32  
33  
34

### 35 **Acknowledgements**

36  
37  
38  
39 *Funding and Role of the Sponsor:* This study was funded by the Canadian Institutes of Health  
40  
41 Research (CIHR). The study sponsors had no role in the design and conduct of the study;  
42  
43 collection, management, analysis, and interpretation of the data; and preparation, review, or  
44  
45 approval of the manuscript. NAK is funded by a Michael Smith Foundation for Health Research  
46  
47 Career Scientist award.  
48  
49  
50

51  
52  
53  
54 *Conflict of Interest:* There are no potential conflicts of interest involving the work under  
55  
56 consideration for publication (during the time involving the work, from initial conception and  
57  
58  
59  
60

1  
2  
3 planning to present), no relevant financial activities outside the submitted work (over the 3 years  
4  
5 prior to submission), and no other relationships or activities that readers could perceive to have  
6  
7 influenced, or that give the appearance of potentially influencing what is written in the submitted  
8  
9 work (based on all relationships that were present during the 3 years prior to submission) for any  
10  
11 of the co-authors.  
12  
13

14  
15  
16  
17  
18 Drs. Nadia Khan and Calvin Ke take full responsibility for the work as a whole, including the  
19  
20 study design, access to data, and the decision to submit and publish the manuscript.  
21  
22

23  
24  
25 **Data Sharing Statement:** all datasets are available through Population Data BC, subject to  
26  
27 approval by relevant data stewards at the BC Ministry of Health.  
28  
29

## 30 31 32 33 34 **References**

- 35  
36  
37 1. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2  
38  
39 Diabetes Mellitus. *N Engl J Med*. 2010;362(17):1575–85.
- 40  
41 2. American Diabetes Association. Standards of Medical Care in Diabetes—2016. *Diabetes*  
42  
43 *Care*. 2016 Jan;39(Supplement 1):S1–112.
- 44  
45 3. Internal Clinical Guidelines Team. Type 2 diabetes in adults [Internet]. United Kingdom:  
46  
47 National Institute for Health and Care Excellence; 2015 Dec [cited 2017 May 10]. Report  
48  
49 No.: NG28. Available from: [https://www.nice.org.uk/guidance/ng28/resources/type-2-  
diabetes-in-adults-management-pdf-1837338615493](https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493)
- 50  
51 4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian  
52  
53 Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management  
54  
55 of Diabetes in Canada. *Can J Diabetes*. 2013 Apr;37(Suppl 1):S1–212.
- 56  
57 5. International Diabetes Federation Guideline Development Group. Global Guideline for  
58  
59 Type 2 Diabetes. *Diabetes Res Clin Pract*. 2014 Apr;104(1):1–52.  
60

- 1  
2  
3 6. Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in  
4 hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and  
5 lisinopril. *JAMA*. 2005 Apr 6;293(13):1595–608.
- 6  
7  
8 7. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, et al. Clinical  
9 outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose  
10 concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to  
11 Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005 Jun 27;165(12):1401–9.
- 12  
13  
14 8. Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better  
15 to calcium blockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers? A  
16 systematic review. *BMC Med*. 2013 May 30;11(1):141.
- 17  
18  
19 9. Mahmoudpour SH, Leusink M, Putten LVD, Terreehorst I, Asselbergs FW, De Boer A, et  
20 al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic  
21 review and meta-analysis. *Pharmacogenomics*. 2013 Feb;14(3):249–60.
- 22  
23  
24 10. Gupta AK. Racial Differences in Response to Antihypertensive Therapy: Does One Size  
25 Fits All? *Int J Prev Med*. 2010;1(4):217–9.
- 26  
27  
28 11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk  
29 of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ*.  
30 1998 Sep 12;317(7160):713–20.
- 31  
32  
33 12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of  
34 nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-  
35 insulin-dependent diabetes and hypertension. *N Engl J Med*. 1998;338(10):645–652.
- 36  
37  
38 13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on  
39 cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the  
40 HOPE study and MICRO-HOPE substudy. *The Lancet*. 2000 Jan 22;355(9200):253–9.
- 41  
42  
43 14. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al.  
44 Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*.  
45 2008 Apr 10;358(15):1547–59.
- 46  
47  
48 15. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ôunpoo S, Lawton WA, et al. Telmisartan to  
49 Prevent Recurrent Stroke and Cardiovascular Events. *N Engl J Med*. 2008 Sep  
50 18;359(12):1225–37.
- 51  
52  
53 16. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. [SHEP]  
54 Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated  
55 systolic hypertension with and without diabetes. *Am J Cardiol*. 2005 Jan 1;95(1):29–35.
- 56  
57  
58 17. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.  
59 Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes.  
60 *J Am Coll Cardiol*. 2010 Jun 29;56(1):77–85.

- 1  
2  
3 18. International Diabetes Federation. IDF Diabetes Atlas [Internet]. International Diabetes  
4 Federation; 2015 [cited 2017 May 6]. Available from:  
5 <http://www.diabetesatlas.org/component/attachments/?task=download&id=116>  
6  
7
- 8 19. Brewster LM, Montfrans GA van, Oehlers GP, Seedat YK. Systematic review:  
9 antihypertensive drug therapy in patients of African and South Asian ethnicity. *Intern*  
10 *Emerg Med*. 2016 Apr 1;11(3):355–74.  
11
- 12 20. BC Ministry of Health Data Stewardship Committee, BC Vital Statistics Agency.  
13 Consolidation File (MSP Registration & Premium Billing); Discharge Abstracts Database  
14 (Hospital Separations) and Medical Services Plan (MSP) Payment Information File;  
15 PharmaNet; Vital Statistics Deaths [Internet]. Population Data BC; BC Ministry of Health;  
16 2012 2014. Available from: <http://www.popdata.bc.ca/data>  
17  
18
- 19 21. Lindsay C. The South Asian Community in Canada [Internet]. Ottawa: Social and  
20 Aboriginal Statistics Division, Statistics Canada; 2001 [cited 2017 May 10]. (Profiles of  
21 Ethnic Communities in Canada). Report No.: 89–621–XIE. Available from:  
22 <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2007006-eng.htm#4>  
23  
24
- 25 22. Lindsay C. The Chinese Community in Canada [Internet]. Ottawa: Social and Aboriginal  
26 Statistics Division, Statistics Canada; 2001 [cited 2017 May 10]. (Profiles of Ethnic  
27 Communities in Canada). Report No.: 89–621–XIE. Available from:  
28 <http://www.statcan.gc.ca/pub/89-621-x/89-621-x2006001-eng.htm>  
29  
30
- 31 23. Chong E, Wang H, King-Shier KM, Quan H, Rabi DM, Khan NA. Prescribing patterns and  
32 adherence to medication among South-Asian, Chinese and white people with type 2  
33 diabetes mellitus: a population-based cohort study. *Diabet Med J Br Diabet Assoc*. 2014  
34 Dec;31(12):1586–93.  
35
- 36 24. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario,  
37 Canada 1995–2005: a population-based study. *The Lancet*. 2007 Mar;369(9563):750–6.  
38  
39
- 40 25. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes  
41 mellitus from administrative data. *Diabetes Res Clin Pract*. 2010 Aug;89(2):189–95.  
42
- 43 26. Khan NA, Wang H, Anand S, Jin Y, Campbell NRC, Pilote L, et al. Ethnicity and sex affect  
44 diabetes incidence and outcomes. *Diabetes Care*. 2011 Jan;34(1):96–101.  
45  
46
- 47 27. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify South  
48 Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study.  
49 *BMC Med Res Methodol*. 2010 May 15;10:42.  
50
- 51 28. Milan A, Maheux H, Chui T. A portrait of couples in mixed unions. *Can Soc Trends*  
52 [Internet]. 2010 Apr 20 [cited 2017 May 6];Summer 2010(89). Available from:  
53 <http://www.statcan.gc.ca/pub/11-008-x/2010001/article/11143-eng.htm>  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 29. Government of Canada SC. Tables by subject: Ethnic diversity and immigration [Internet].  
4 2013 [cited 2017 May 6]. Available from: <http://www.statcan.gc.ca/tables-tableaux/sum->  
5 som/l01/ind01/12\_30000-eng.htm  
6  
7
- 8 30. Hanley GE, Morgan S. On the validity of area-based income measures to proxy household  
9 income. *BMC Health Serv Res*. 2008 Apr 10;8:79.  
10
- 11 31. Monami M, Lambertucci L, Lamanna C, Lotti E, Marsili A, Masotti G, et al. Are  
12 comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients?  
13 Comparison between Charlson index and disease count. *Aging Clin Exp Res*. 2007  
14 Dec;19(6):492–6.  
15
- 16 32. Brunner NW, Ramanathan K, Wang H, Quan H, Khan NA. Effectiveness of Statin  
17 Prescribing on Reducing Mortality in South Asian, Chinese, and White Patients With  
18 Diabetes. *Can J Cardiol*. 2013 Aug;29(8):920–6.  
19
- 20 33. Mansournia MA, Altman DG. Inverse probability weighting. *BMJ*. 2016 Jan 15;352:i189.  
21
- 22 34. Mansournia MA, Danaei G, Forouzanfar MH, Mahmoodi M, Jamali M, Mansournia N, et  
23 al. Effect of Physical Activity on Functional Performance and Knee Pain in Patients With  
24 Osteoarthritis: Analysis With Marginal Structural Models. *Epidemiology*. 2012  
25 Jul;23(4):631–40.  
26
- 27 35. Gharibzadeh S, Mohammad K, Rahimiforushani A, Amouzegar A, Mansournia MA.  
28 Standardization as a Tool for Causal Inference in Medical Research. *Arch Iran Med*. 2016  
29 Sep;19(9):666–70.  
30
- 31 36. Austin PC. The use of propensity score methods with survival or time-to-event outcomes:  
32 reporting measures of effect similar to those used in randomized experiments. *Stat Med*.  
33 2014 Mar 30;33(7):1242–58.  
34
- 35 37. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for  
36 standardizing adherence measures derived from administrative claims data among diabetic  
37 patients. *Med Care*. 2008;46(11):1125–1133.  
38
- 39 38. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al.  
40 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan  
41 Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial  
42 against atenolol. *The Lancet*. 2002 Mar 23;359(9311):1004–10.  
43
- 44 39. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K. Antihypertensive medication  
45 prescribing in 27,822 elderly Canadians with diabetes over the past decade. *Diabetes Care*.  
46 2006;29(4):836–841.  
47
- 48 40. Khan NA, Grubisic M, Hemmelgarn B, Humphries K, King KM, Quan H. Outcomes After  
49 Acute Myocardial Infarction in South Asian, Chinese, and White Patients. *Circulation*.  
50 2010 Oct 19;122(16):1570–7.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
- 2
- 3
- 4 41. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for
- 5 public health. *Int J Epidemiol*. 2009 Jun 1;38(3):791–813.
- 6
- 7 42. Yip VLM, Pirmohamed M. Expanding Role of Pharmacogenomics in the Management of
- 8 Cardiovascular Disorders. *Am J Cardiovasc Drugs*. 2013 Jun;13(3):151–62.
- 9
- 10 43. Tsoi KKF, Wong MCS, Tam WWS, Hirai HW, Lao XQ, Wang HHX, et al. Cardiovascular
- 11 mortality in hypertensive patients newly prescribed perindopril vs. lisinopril: A 5-year
- 12 cohort study of 15,622 Chinese subjects. *Int J Cardiol*. 2014 Oct 20;176(3):703–9.
- 13
- 14 44. Wang L, Kwak M-J. Immigration, barriers to healthcare and transnational ties: A case study
- 15 of South Korean immigrants in Toronto, Canada. *Soc Sci Med* 1982. 2015 May;133:340–8.
- 16
- 17 45. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, et al. Do
- 18 observational studies using propensity score methods agree with randomized trials? A
- 19 systematic comparison of studies on acute coronary syndromes. *Eur Heart J*. 2012 Aug
- 20 1;33(15):1893–901.
- 21
- 22 46. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-Pressure and
- 23 Cholesterol Lowering in Persons without Cardiovascular Disease. *N Engl J Med*. 2016 May
- 24 26;374(21):2032–43.
- 25
- 26 47. Hernán MA. The Hazards of Hazard Ratios. *Epidemiol Camb Mass*. 2010 Jan;21(1):13–5.
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



**Table 1** Baseline characteristics among diabetes patients aged 35 years and older\*. Chi-square tests and analyses of variance showed statistically significant differences among the three groups ( $p < 0.0001$ ) for all baseline characteristics.

Characteristics	South Asian ( <i>n</i> =13 755)	Chinese ( <i>n</i> =22 871)	Other ( <i>n</i> =172 244)
Age, mean age (years) $\pm$ SD or %			
All patients	56.4 $\pm$ 12.6	59.2 $\pm$ 12.7	61.5 $\pm$ 12.8
35-49 years	33.2	24.7	18.8
50-64 years	39.8	43.1	42.0
65-79 years	23.2	25.3	29.5
$\geq$ 80 years	3.87	6.8	9.7
Women (%)	45.0	48.4	45.1
Income Quintile (%)			
1 <sup>st</sup> quintile (low)	25.6	27.4	21.2
2 <sup>nd</sup> quintile	32.2	23.4	20.7
3 <sup>rd</sup> quintile	20.4	20.2	20.0
4 <sup>th</sup> quintile	12.3	14.4	19.3
5th quintile (high)	8.8	13.4	17.5
Unknown	0.7	1.0	1.2
Comorbidities (%)			
Hypertension	42.0	44.0	47.9
Myocardial infarction	2.2	1.0	2.6
Congestive heart failure	3.0	2.1	5.3
Peripheral vascular disease	0.6	1.3	2.0
Cancer	2.8	3.8	6.3
Cerebrovascular disease	1.8	2.0	3.2
Chronic pulmonary disease	11.2	6.4	11.4
Renal disease	2.2	2.3	3.1
Medications prescribed at baseline <i>n</i> (%)			
ACEi	15.7	11.0	22.8
ARB	7.2	10.0	8.7
CCB	8.1	9.1	8.5
Diuretic	11.3	12.4	18.3
$\beta$ -blocker	9.5	8.4	13.3
Metformin	21.3	15.4	23.8
Sulfonylurea	3.8	2.6	3.5
Insulin	0.6	0.7	1.7
Statin	24.2	20.8	26.9
Medications prescribed after 1 year of diabetes diagnosis <i>n</i> (%)			
ACEi	26.1	17.8	33.5
ARB	12.6	16.3	13.7
CCB	12.6	13.9	12.8
Diuretic	18.7	18.6	27.0



Any ACEi, ARB, CCB, diuretic**	55.2	47.7	64.9
--------------------------------	------	------	------

\*All p-values comparing the 3 ethnic groups were less than 0.001

\*\*Abbreviations: SD = standard deviation, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 2** Association between antihypertensive medications and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian		Chinese		Other	
	HR	p-value	HR	p-value	HR	p-value
ACEi	0.91 (0.71-1.17)	0.47	0.84 (0.69-1.03)	0.09	0.88 (0.84-0.91)	<0.0001
ARB	0.88 (0.63-1.25)	0.48	0.64 (0.50-0.82)	0.0004	0.69 (0.64-0.74)	<0.0001
CCB	1.25 (0.93-1.68)	0.14	0.94 (0.77-1.15)	0.56	1.00 (0.94-1.05)	0.89
Diuretic	0.83 (0.61-1.12)	0.22	0.77 (0.62-0.96)	0.02	0.66 (0.63-0.69)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

**Table 3** Association between medication adherence and all-cause mortality according to ethnicity

Drug	Adjusted HR* (95% CI)					
	South Asian (n=9404)	p-value	Chinese (n=13 173)	p-value	Other (n=124 594)	p-value
Any ACEi, ARB, CCB, diuretic <sup>†</sup>	1.11 (0.71-1.73)	0.65	1.29 (0.83-2.01)	0.25	0.79 (0.72-0.86)	<0.0001

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

<sup>†</sup> Hazard ratios for patients prescribed any antihypertensive (ACEi, ARB, CCB, diuretic) with moderate or high adherence compared to low adherence

1  
2  
3 Abbreviations: HR = hazard ratio, ACEi = angiotensin converting enzyme inhibitor, ARB =  
4 angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker  
5  
6  
7

8 **Figure 1** Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and  
9 diuretics (“DIU”) according to ethnicity: (A) South Asian; (B) Chinese; (C) Other  
10

11 *(see Figure 1A, 1B, 1C files attached separately)*  
12

13  
14 \* Cox proportional hazards models were weighted using a propensity score model by the IPTW  
15 method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin,  
16 ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription  
17 within 1 month before or after diagnosis.  
18

19 Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor  
20 blocker, CCB = dihydropyridine calcium channel blocker  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1A. Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics ("DIU") according to ethnicity: (A) South Asian; (B) Chinese; (C) Other

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

169x169mm (300 x 300 DPI)




Figure 1B. Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics (“DIU”) according to ethnicity: (A) South Asian; (B) Chinese; (C) Other

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

169x169mm (300 x 300 DPI)




Figure 1C. Cumulative incidence of death\* for patients treated with ACEi, ARB, CCB, and diuretics ("DIU") according to ethnicity: (A) South Asian; (B) Chinese; (C) Other

\* Cox proportional hazards models were weighted using a propensity score model by the IPTW method adjusted for age, sex, SES, Charlson comorbidities, and use of other medications (insulin, ACEi, ARB, beta-blockers, CCB, diuretics, and statins) at baseline, defined as a prescription within 1 month before or after diagnosis.

Abbreviations: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CCB = dihydropyridine calcium channel blocker

169x169mm (300 x 300 DPI)

## Appendix I. Supplemental Tables

**Supplemental Table S1** Statistical power for each drug by ethnicity calculated using the log-rank test (two-sided  $\alpha=0.05$ ), specifying actual sample sizes, treatment and event rates observed, allocation ratio, and hazard ratio as derived from the risk reduction observed in major clinical trials cited below and in the manuscript. The same expected risk reduction was used for CCB and diuretics because the ALLHAT study utilized an active comparator instead of a placebo control, showing no significant difference between effectiveness of amlodipine and chlorthalidone in reducing all-cause mortality.

	Hazard ratio	Power		
		South Asian	Chinese	Other
ACEi	0.76	0.77	0.87	>0.999
ARB	0.61	0.96	>0.999	>0.999
CCB	0.80	0.40	0.62	>0.999
Diuretic	0.80	0.51	0.72	>0.999

Abbreviations: angiotensin-converting enzyme inhibitor, ACEi; angiotensin receptor blocker, ARB; calcium channel blocker, CCB

**Supplemental Table S2** Mean and standard deviation of stabilized inverse probability weights

Ethnicity	Estimated Weights	
	Mean	Standard Deviation
South Asian	0.98	0.42
Chinese	0.98	0.33
Other	0.98	0.46

## References

1. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *The Lancet*. 2000 Jan 22;355(9200):253–9.
2. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547–59.
3. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2005 Jun 27;165(12):1401–9.
4. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. *The American Journal of Cardiology*. 2005 Jan 1;95(1):29–35.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract <b>[title page 1 and abstract page 2]</b> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>[abstract page 2]</b>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>[introduction page 4]</b>
Objectives	3	State specific objectives, including any prespecified hypotheses <b>[introduction page 5]</b>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper <b>[methods page 5]</b>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>[methods pages 5-7]</b>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>[methods pages 5-8]</b> <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <b>[methods page 9]</b> <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>[methods pages 7-9]</b>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>[methods pages 8-9]</b>
Bias	9	Describe any efforts to address potential sources of bias <b>[methods page 9]</b>
Study size	10	Explain how the study size was arrived at <b>[methods page 6]</b>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>[methods page 9]</b>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>[methods pages 9-10]</b> (b) Describe any methods used to examine subgroups and interactions N/A (c) Explain how missing data were addressed N/A (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed N/A <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses <b>[methods page 9]</b>

Continued on next page

For peer review only

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [ <b>results page 10</b> ] (b) Give reasons for non-participation at each stage <b>N/A</b> (c) Consider use of a flow diagram <b>N/A</b>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [ <b>page 21 Table 1</b> ] (b) Indicate number of participants with missing data for each variable of interest [ <b>page 21 Table 1</b> ] (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) [ <b>results page 11</b> ]
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time [ <b>results page 11</b> ] <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [ <b>page 22 Table 2</b> ] (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [ <b>page 22 Table 3</b> ]

**Discussion**

Key results	18	Summarise key results with reference to study objectives [ <b>Discussion page 12</b> ]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [ <b>Discussion page 15</b> ]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [ <b>Discussion pages 12-15</b> ]
Generalisability	21	Discuss the generalisability (external validity) of the study results [ <b>Discussion page 15</b> ]

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [ <b>page 16</b> ]
---------	----	--

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).